


A TEXTBOOK OF PATHOPHYSIOLOGY

ISBN: 978-81-985724-1-7



DOI 10.5281/zenodo.15399027

Chapter- 2

Comprehensive Guide to Cardiovascular, Respiratory, And Renal Disorders

MR. SHAILENDRA VERMA

Assistant Professor

Teerthankar Mahaveer University,
Moradabad 244001

Email: shailendra1993vermaji@gmail.com

DR SANDESH LONDHE (PT)

HOD, Professor (Cardiovascular &
Respiratory PT),

Ojas College of Physiotherapy, Jalna

DR. MOIDUL ISLAM JUDDER

Assistant Professor

Royal School of Pharmacy, The Assam
Royal Global University, Betkuchi, Opp.
Tirupati Balaji Temple, NH 37, Guwahati -
781035, Assam, India

Email - moonzodder@gmail.com

MS. NEHA MANDLE

Assistant Professor

Institute address- Shri Shankaracharya
College of Pharmaceutical sciences Junwani
Bhilai

Pin – 490020

MR. DELESHWAR KUMAR

Assistant Professor

Institute address - Kamla Institute of
Pharmaceutical Sciences, junwani, Bhilai
Pin 490020

Unit II...

**COMPREHENSIVE GUIDE TO
CARDIOVASCULAR, RESPIRATORY, AND
RENAL DISORDERS**

MR. SHAILENDRA VERMA

Assistant Professor

Teerthankar Mahaveer University, Moradabad 244001

Email: shailendra1993vermaji@gmail.com

DR SANDESH LONDHE (PT)

HOD, Professor (Cardiovascular & Respiratory PT),

Ojas College of Physiotherapy, Jalna

DR. MOIDUL ISLAM JUDDER

Assistant Professor

Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Opp. Tirupati

Balaji Temple, NH 37, Guwahati - 781035, Assam, India

Email - moonzodder@gmail.com

MS. NEHA MANDLE

Assistant Professor

Institute address- Shri Shankaracharya College of Pharmaceutical sciences Junwani Bhilai

Pin – 490020

MR. DELESHWAR KUMAR

Assistant Professor

Institute address - Kamla Institute of Pharmaceutical Sciences, junwani, Bhilai

Pin 490020

2.1 Cardiovascular System

2.1.1 Hypertension

An ongoing medical disease that is characterized by consistently higher blood pressure in the arteries is referred to as hypertension, which is also referred to as high blood pressure. The force that the blood exerts against the walls of the arteries as it is pumped around the body by the heart is referred to as circulation pressure. As a result of a variety of activities, feelings, and periods of rest, a healthy person's blood pressure will fluctuate during the course of the day. On the other hand, that pressure stays continuously high in a person who has hypertension, which puts an unnecessary burden on the heart and the blood arteries.




Figure 1: Hypertension

Hypertension can have a significant and far-reaching impact on the body with its effects. As a result of the persistent elevation of pressure in the arteries, the heart is compelled to exert more effort in order to pump blood. This, in turn, causes the heart muscle to get thicker, which may eventually lead to heart failure. Atherosclerosis is a disorder that occurs when fatty deposits or plaques accumulate in the arteries. This condition can be caused by persistent pressure, which can also cause damage to the delicate inner lining of the arteries. In turn, this raises the risk of developing coronary artery disease and other cardiovascular problems, which can lead to heart attacks and strokes. High blood pressure, or hypertension, is a leading cause of kidney failure

because it damages the kidneys' blood vessels, which reduces the kidneys' ability to filter waste thoroughly.

Hypertension is frequently referred to as the "silent killer" due to the fact that it typically does not display apparent signs until severe damage has occurred. This is one of the biggest challenges associated with hypertension. As hypertension continues to develop without being recognized, a significant number of people who have it may be unaware of their disease for years. Headaches, shortness of breath, and nosebleeds are examples of symptoms that may appear in some cases; however, in general, these symptoms are typical of hypertension that is severe or advanced. Monitoring blood pressure on a consistent basis is essential for early detection and management of hypertension due to the insidious nature of the condition.

One of the easiest methods for diagnosing hypertension is to use a sphygmomanometer to take a reading of the patient's blood pressure. The systolic pressure, which is the pressure that occurs when the heart beats, is increased by the diastolic pressure, which is the pressure that occurs while the heart rests between beats. This is how blood pressure values are presented. The usual range for blood pressure readings is approximately 120 over 80 millimeters of mercury. When repeated measures consistently show a value of 130/80 mmHg or greater, hypertension is established as a diagnostic condition. The management of hypertension typically entails a combination of alterations to one's lifestyle and the use of medicines once the condition has been recognized.

Modifying one's way of life is the initial step in controlling hypertension. As part of these changes, you may want to eat more heart-healthy foods like fruits, vegetables, whole grains, and lean meats and cut back on processed foods, saturated fats, and salt. Exercising regularly, keeping a healthy weight, minimizing stress, and quitting smoking are other crucial components of managing blood pressure. These steps, if taken together, may be enough to control hypertension for many people. When changes in lifestyle are not enough to lower blood pressure and the risk of complications, medical experts may prescribe medication such as beta-blockers, diuretics, angiotensin-converting enzyme inhibitors, or calcium channel blockers.

To summarize, hypertension is a significant public health risk that calls for diligent monitoring, early detection, and proactive management for the condition. The long-term implications of uncontrolled high blood pressure can be disastrous, despite the fact that it frequently does not present any symptoms that are noticeable. It is possible for people who have hypertension to effectively manage their condition, minimize their risk of significant health problems, and live

healthier and longer lives by making changes to their lifestyle and, when necessary, taking additional drugs.

2.1.2 Congestive heart failure

Congestive heart failure, also known as CHF, is an illness that is both complex and chronic. It is characterized by a reduction in the heart's capacity to pump blood effectively, which results in a chain reaction of symptoms and consequences that spread throughout the body. The chronic heart failure (CHF) problem is a progressive ailment that develops over time as the heart becomes more unable to meet the demands of the body for blood and oxygen. This is in contrast to a heart attack, which is an acute event. The inadequacy might be the result of a number of underlying illnesses, including coronary artery disease, hypertension, valvular heart disease, or cardiomyopathy. Each of these conditions contributes to the weakening or stiffening of the heart muscle.




Figure 2: Normal vs congestive heart

Blood is effectively pumped through the chambers of a healthy heart and out to the rest of the body. This allows the heart to supply the tissues and organs with the oxygen and nutrients that they require in order to operate properly. On the other hand, congestive heart failure is characterized by a reduction in the pumping capacity of the heart, which results in the accumulation of blood in the veins that flow to the heart. Fluid collection occurs in many

regions of the body as a result of this backup, most commonly in the lungs (pulmonary congestion) and the lower limbs (peripheral edema). The term "congestive" in congestive heart failure (CHF) refers specifically to this accumulation of fluid, which is a characteristic feature of the condition.

Patients who have congestive heart failure frequently experience a wide variety of incapacitating symptoms as a result of the decreased cardiac output and fluid overload. One of the most prevalent and distressing symptoms is shortness of breath, which frequently becomes worse with physical activity or even while lying down (something that is referred to as orthopnea here). The fluid that is present in the lungs causes this to happen because it disrupts the regular breathing process. Another common symptom is fatigue, which occurs when the tissues of the body receive less oxygenated blood. This results in a fall in energy levels and an overall feeling of depletion. In addition, swelling, also known as edema, is usually noted in the legs, ankles, and feet. This is a consequence of the buildup of extra fluid in these areas. Patients who are in more advanced stages of the disease may also develop arrhythmias, which are characterized by rapid or irregular heartbeats, chronic coughing or wheezing, and a diminished capacity to engage in physical activity or carry out everyday activities.

The course of congestive heart failure can vary widely from one individual to the next, depending on the underlying cause of the condition as well as the efficacy of the treatment regimen currently being utilized. When it comes to reducing the progression of the disease and enhancing one's quality of life, early diagnosis and management are absolutely necessary. The clinical evaluation, imaging examinations, and laboratory tests that are routinely used in the diagnostic process are all brought together. The non-invasive imaging technique known as echocardiography is frequently utilized for the purpose of assessing the anatomy and function of the heart. On the other hand, blood tests have the potential to show biomarkers that are symptomatic of heart failure, such as elevated levels of B-type natriuretic peptide (BNP).

CHF is managed in a variety of ways, each of which is individualized to meet the requirements of the patient. The reduction of symptoms, the enhancement of quality of life, and the prevention of further advancement of the disease are the key objectives of therapeutic efforts. The majority of the time, this calls for a mix of alterations to one's way of life, the use of drugs, and in some instances, surgical treatments. Modifications to one's lifestyle, such as reducing sodium intake to prevent fluid retention, engaging in regular physical activity to strengthen the

heart muscle, and giving up smoking to reduce cardiovascular strain, are all important components in the management of congestive heart failure (CHF).

Medication plays a crucial role in the treatment of congestive heart failure (CHF), and it is prescribed to patients based on their individual requirements. In order to assist the body in eliminating excess fluid, diuretics are frequently utilized. This enables the body to reduce swelling and alleviate symptoms such as shortness of breath. Beta-blockers and ACE inhibitors are popular medications that are prescribed to patients in order to lower blood pressure, lessen the workload placed on the heart, and improve overall cardiac function. In situations where these treatments are not sufficient, surgical options may be considered. These include the implantation of a pacemaker or defibrillator, or in more severe cases, a heart transplant.

The management of congestive heart failure must be ongoing, and patients must maintain regular follow-up appointments with their healthcare providers. In order for patients to properly manage their disease, they need to be careful about monitoring their symptoms, adhering to their treatment regimens, and making any required alterations to their lifestyle. In spite of the fact that CHF is a chronic condition, many people are able to keep their quality of life high with the right kind of care and treatment. However, the condition may get more severe with time, which may require adjustments to be made to the treatment. Individuals who suffer congestive heart failure (CHF) have seen considerable improvements in their outcomes as a result of continual discoveries in medical therapies and a better knowledge of the disease. These developments have provided those who are afflicted with this severe ailment with greater quality of life and optimism.

2.1.3 Ischemic heart disease

Ischemic heart disease, also known as IHD, is a broad term that encompasses a variety of disorders that are brought on by inadequate blood supply to the heart muscle. This is typically brought on by coronary artery disease, also known as CAD. The heart's capacity to obtain sufficient oxygen and nutrients is hindered as a result of this decreased blood flow, which can result in major cardiovascular issues. Angina, which is characterized by chest pain or discomfort, is one of the most common characteristics of ischemic heart disease (IHD). Angina arises when the heart muscle does not receive sufficient amounts of oxygen-rich blood. There are two types of angina: stable, which occurs reliably with effort, and unstable, which occurs unexpectedly and may be an indication of a more serious underlying problem.




Figure 3: Ischemic heart disease

Myocardial infarction, more frequently referred to as a heart attack, is another devastating form of coronary heart disease (CHD). This condition manifests itself when a coronary artery becomes fully blocked, which ultimately results in the death of heart muscle tissue as a consequence of a protracted absence of blood flow by the heart. The damage that can be caused by a myocardial infarction can be significant, which can lead to a permanent loss in the heart's capacity to pump blood adequately. In order to restore blood flow and reduce the amount of damage done to the heart, this serious consequence frequently need prompt medical intervention.

Atherosclerosis is a condition that is closely connected with coronary heart disease (CHD). It is characterized by the accumulation of plaques, which are fatty deposits, on the inner walls of the coronary arteries. Plaques like this have the potential to narrow and stiffen the arteries, which, in turn, reduces the flow of blood and raises the risk of blood clot development. Both angina and myocardial infarction are greatly influenced by the existence of atherosclerosis, which poses a considerable risk factor for both conditions. Another condition that is connected to atherosclerosis is called arteriosclerosis, and it is characterized by the thickening and hardening of the walls of the arteries. This condition further reduces blood flow and raises the risk of cardiovascular events.

Ischemic heart disease, in its broadest sense, refers to a collection of disorders that, when taken together, constitute a considerable burden on the health of the cardiovascular function. The interaction between decreased blood flow, atherosclerosis, and arteriosclerosis shows the multidimensional nature of coronary heart disease (CHD) and emphasizes the significance of early detection, management, and lifestyle modifications in order to limit the impact of this potentially life-threatening condition.

❖ Angina

Inadequate blood flow to the heart muscle causes chest pain or discomfort, which is known as angina, a symptom of ischemic heart disease. If you suffer from this illness, you can find that your shoulders, neck, chin, or arms start to tighten up as well as your chest feels squeezed or squeezed. Pain from angina usually happens when the heart needs more oxygen-rich blood than it can get. Physical activity, emotional tension, or eating a heavy meal are common triggers for this. When the heart muscle experiences transient ischemia due to an imbalance between oxygen supply and demand, it causes the discomfort that is known as angina.




Figure 4: Angina

A primary distinction can be made between two types of anginas, each of which has a unique set of characteristics and management implications. A more predictable form of angina is known as stable angina, which is typically brought on by particular activities or stressors such as emotional strain or physical exertion among other things. It is common for the chest pain that is associated with stable angina to be temporary and to disappear after a period of rest or after the administration of medications such as nitroglycerin, which help to alleviate the symptoms by increasing the amount of blood that flows to the heart. In most cases, stable

angina can be managed through the implementation of lifestyle changes and the implementation of medication. Additionally, stable angina serves as an indication of underlying coronary artery disease, which may necessitate ongoing monitoring and intervention.

Unstable angina, on the other hand, is a form of the condition that is more severe and less predictable than other types. In contrast to stable angina, it can happen when the patient is at rest or when they are exerting themselves very little, and the pain is typically more intense and lasts for a longer period of time. Unstable angina is a more concerning symptom because it does not always respond to standard treatments like rest or nitroglycerin. This presents a challenge for medical professionals. Due to the fact that it may be an indication that a heart attack is about to occur or that there is a significant worsening of the underlying coronary artery disease, this type of angina is regarded as a medical emergency. If you have unstable angina, it is imperative that you seek medical attention as soon as possible in order to avoid any potential complications and to effectively manage the elevated risk of myocardial infarction.

2.1.4 Types of Anginas

➤ Angina that is stable

The predictability of stable angina in reaction to particular triggers, such as physical activity or mental stress, is one of the defining characteristics of this type of angina. The symptoms of this type of angina often include chest pain or discomfort that lasts for a few minutes and goes away when the patient rests or takes drugs like nitroglycerin. In most cases, the symptoms can be managed with the implementation of lifestyle modifications, such as alterations to one's diet, regular exercise, and stress management, in addition to the utilization of pharmacological therapies. It is common for stable angina episodes to reoccur, which is a sign that the underlying coronary artery disease is present. In order to avoid the progression of this condition, continuous monitoring and care are required. When it comes to stable angina, some of the most common causes include engaging in physical activities, experiencing emotional stress, being exposed to cold weather, or eating heavy meals. As a result of the temporary nature of the ischemia that is experienced during these episodes, the pain typically disappears quickly when the triggering event is removed or after medicine is administered.




Figure 5: Types of Anginas

➤ **Angina that is unstable**

The unpredictability and severity of unstable angina are two important ways in which it differs dramatically from stable angina. Conventional treatments, such as rest or nitroglycerin, may not always be effective in treating this condition, which frequently manifests as chest discomfort that is more acute and lasts for a longer period of time. It can happen at rest or with minimal exercise. The presence of this type of angina indicates an increased risk of acute coronary events, which causes it to be considered a medical emergency that requires rapid attention. In unstable angina, the pain that is linked with the condition may occur more frequently, may be more severe, and may continue for a longer period of time than unstable angina episodes. Because unstable angina may be a precursor to a myocardial infarction, it is essential to seek medical assessment and treatment as soon as possible in order to reduce the likelihood of a heart attack and effectively manage the coronary artery disease that is the underlying cause of the condition. The fact that unstable angina has the potential to suggest a major decline in cardiac health highlights the critical nature of managing this condition as soon as possible.

Diagnosis and Evaluation

➤ The Clinical Background

The first step in diagnosing angina is to conduct a detailed clinical history, which includes an in-depth evaluation of the patient's symptoms, the factors that bring them on, and how they react to rest and medicine. The nature of the chest pain or discomfort is meticulously documented by the healthcare providers during this evaluation. This includes the start, length, and degree of the pain or discomfort, as well as any related symptoms such as shortness of breath, nausea, or sweating. In order to differentiate between stable and unstable angina, it is essential to identify the exact triggers that induce the pain. These triggers may include physical effort, mental stress, or heavy meals. It is also important to observe the patient's reaction to rest and drugs, notably nitroglycerin, because this can assist in distinguishing angina from other possible causes of chest discomfort. Healthcare professionals are able to make a more accurate diagnosis and choose the right diagnostic tests and treatment procedures when they have a thorough understanding of the pattern and characteristics of the symptoms.

➤ Testing for Diagnosis

There are a number of diagnostic tests that are employed in order to confirm a diagnosis of angina and evaluate the severity of coronary artery disease. Electrocardiograms, often known as ECGs, are among the most common diagnostic procedures that are utilized to identify abnormalities in the electrical activity of the heart. These abnormalities may be indicative of ischemia or a previous myocardial infarction. For the purpose of determining how the heart reacts to increased workload or stress, stress tests, such as those performed on exercise treadmills or pharmacological stress tests, are utilized. In order to identify ischemia changes that take place as a result of physical effort, several tests are helpful. The coronary angiography procedure is carried out in situations where the results of non-invasive diagnostics are inconclusive. During this invasive technique, a contrast dye is injected into the coronary arteries, and X-ray images are taken in order to visualize any blockages or narrowing that may be present in the arteries. In order to offer comprehensive information regarding the extent and location of coronary artery disease, coronary angiography is performed. This information directs subsequent treatment decisions.

➤ **Review of the Dangers**

The evaluation of the patient's cardiovascular risk factors and general heart health is the primary emphasis of the risk assessment, which is an essential component of the diagnostic procedure. For the purpose of this evaluation, parameters such as age, gender, smoking status, blood pressure, cholesterol levels, and the existence of illnesses such as diabetes or obesity are taken into consideration alongside other aspects. In order to predict the patient's risk of future cardiovascular events based on these characteristics, it is possible to make use of tools such as the Framingham Risk Score or the ASCVD (Atherosclerotic Cardiovascular Disease) Risk Calculator. The ability to personalize treatment and prevention methods to target particular risk factors and enhance overall cardiovascular health is made possible for healthcare practitioners when they have a thorough awareness of the risk profile of the patient. The development of a personalized management plan that aims to lower the possibility of angina progression and prevent major consequences such as myocardial infarction is facilitated by exhaustive risk assessment, which assists in the process of its creation.

Treatment and Management

➤ **Alterations to One's Way of Life**

Modifications to one's lifestyle that are targeted at enhancing one's cardiovascular health in general are frequently the starting point for effective management of angina. It is essential to adopt a diet that is healthy for the heart, which involves decreasing the amount of saturated fats, cholesterol, and sodium that one consumes while simultaneously increasing the number of fruits, vegetables, whole grains, and lean proteins that one consumes. These kinds of dietary adjustments can assist in the management of blood pressure and cholesterol levels, hence lowering the chance of developing coronary artery disease in the future. Physical activity on a consistent basis is also an essential component of treatment since it assists in the management of weight, the improvement of cardiovascular fitness, and the reduction of the strain placed on the heart. With the intention of engaging in physical activity on the majority of days of the week, exercise should be adapted to the capabilities of the individual and typically consists of activities that are considered to be moderate in intensity, such as walking, cycling, or swimming. Additionally, effective stress management practices, such as relaxation exercises, mindfulness, and cognitive-behavioral tactics, can help decrease the emotional and physiological stressors that may trigger angina episodes. These stressors include things like excessive stress, anxiety, and depression. When taken as a whole, these alterations to lifestyle

not only alleviate symptoms but also contribute to the long-term health of the cardiovascular system and the prevention of the course of the disease.

➤ **Pharmaceuticals**

Pharmacological treatment is essential for the management of angina and the avoidance of complications related to coronary artery disease. Medications containing nitrates are commonly used to treat angina. Their mechanism of action involves widening blood arteries, which in turn increases blood flow to the heart muscle. These medications, which include nitroglycerin, provide temporary relief from angina symptoms and can be administered orally, topically, or through patches. Another important part of treating angina is using beta-blockers. Medication for high blood pressure and slowing the heart rate lessens the workload and oxygen demands on the heart. By dilating and relaxing the coronary arteries, calcium channel blockers also contribute. This enhances blood circulation to the heart, which helps lessen the intensity and frequency of angina episodes. Medications that inhibit platelet function, such as aspirin or clopidogrel, are often prescribed to patients at risk of myocardial infarction to lower their risk of blood clot formation. Each patient's specific needs are considered when determining the optimal combination of these medications; factors such as symptom severity and total risk of cardiovascular disease are taken into consideration.



Figure 6: pharmaceuticals

➤ **The Procedures of Medicine**

It may be essential to perform more intrusive medical operations on people who have severe or refractory angina, which is characterized by an inability to respond adequately to lifestyle changes and medicines. The introduction of a balloon catheter into the coronary artery that is

blocked is the procedure that is known as angioplasty, which is sometimes referred to as percutaneous coronary intervention (PCI). It is possible to put a stent in order to maintain the artery's openness after the balloon has been inflated in order to restore normal blood flow and expand the artery. This operation has the potential to provide significant relief from the symptoms of angina and to improve the overall function of the heart. CABG, or coronary artery bypass grafting, is an option that may be considered in situations where angioplasty is either not possible or has been unsuccessful. Through the use of grafts taken from other areas of the body, such as the saphenous vein or the internal mammary artery, coronary artery bypass surgery (CABG) includes the surgical creation of a bypass around blocked coronary arteries. The purpose of this surgery is to enhance blood flow to the heart muscle, alleviate symptoms, and lower the chance of having a heart attack. In order to determine which surgery to do, it is necessary to consider the size and location of coronary artery blockages, as well as the patient's overall health and the particular treatment goals.

Prevention and Long-term Care

It is necessary to take a multi-pronged approach in order to manage long-term care and prevent the advancement of angina. This approach should include regular monitoring, patient education, and comprehensive support. Follow-up appointments with medical professionals on a consistent basis are necessary for the ongoing assessment of the patient's heart health and the modification of treatment regimens. At these appointments, the symptoms can be monitored, the success of treatment can be evaluated, and any necessary adjustments to the prescription or lifestyle advice can be made. Tests and screenings that are performed on a regular basis assist to ensure that any changes in the patient's health are swiftly treated, which in turn helps to reduce the risk of problems and maintain good cardiac function.

When it comes to the long-term management of angina, patient education is an extremely important factor. The empowerment of patients to take an active role in their own health is achieved by the education of patients regarding the recognition of the symptoms of angina, the awareness of the triggers that intensify their disease, and the adherence to the treatment programs that have been recommended. Education like this typically includes information on how to handle episodes of angina, when to seek medical treatment, and the significance of making adjustments to one's lifestyle, such as changing one's diet and engaging in physical activity. Patients are more positioned to properly manage their angina and to make informed

decisions regarding their health outcomes when they have a thorough grasp of their illness and the treatment options available to them.

Individuals who are living with angina must also recognize the importance of receiving support from their families, healthcare experts, and support groups. Support on an emotional and psychological level can be of great assistance to patients in managing the tension and worry that are frequently associated with chronic diseases. In addition to addressing concerns and providing ways to manage both the physical and emotional elements of angina, healthcare practitioners offer counsel and comfort to patients. The members of the family play a helpful role by providing emotional support and urging the patient to comply to the treatment programs. In addition, support groups offer a forum in which individuals can discuss their experiences and methods with others who are going through comparable difficulties, so building a sense of community and greater comprehension. When taken as a whole, these components of support can improve the patient's quality of life and contribute to the more efficient management of angina over the long term.

2.2 Respiratory system

It is the complex network of organs and structures that make up the respiratory system that is responsible for the critical process of gas exchange, which includes the intake of oxygen and the evacuation of carbon dioxide. This system is responsible for ensuring that oxygen is given to the bloodstream and that carbon dioxide, which is a byproduct of metabolism, is removed from the body. It plays a critical part in the maintenance of the body's homeostasis. Each of the upper and lower respiratory tracts, as well as the related structures including the lungs, diaphragm, and pleurae, are included in the respiratory system.




Figure 7: Respiratory system

Nasal cavity, pharynx, and larynx are all components of the upper respiratory tract, which is also known as the upper respiratory system. Through the nasal cavity, air is sent into the respiratory system, where it is filtered, heated, and humidified before entering the system. There are mucous membranes and cilia, which are very little structures that resemble hair and are responsible for capturing dust, pathogens, and other particles that are present in the nasal passages. Following this, the air travels via the pharynx, also known as the throat, and enters the larynx, also known as the voice box. The larynx is the location of the vocal cords and serves as a gateway to the lower respiratory system. In addition, the larynx serves as a protective barrier, preventing food and liquids from entering the trachea during the process of swallowing.

Lower Respiratory Tract: The trachea, bronchi, bronchioles, and alveoli are the components that make up the lower respiratory tract. The trachea, also referred to as the windpipe, is a tube that extends from the larynx and separates into two major bronchi, each of which leads to a lung. The bronchi then divide into smaller bronchioles, which ultimately lead to the alveoli, which are the little air sacs that are responsible for the process of gas exchange. Because the alveoli are surrounded by a network of capillaries, they are able to facilitate the movement of

oxygen from the air into the blood and the movement of carbon dioxide from the blood into the air. The effectiveness of this gas exchange process is essential for ensuring that the bloodstream contains an adequate amount of oxygen and for eliminating waste products that are produced by the metabolic process.

Lungs: The lungs are a pair of organs that are located in the thoracic cavity. They are protected by the pleurae, which are two thin membranes that also create pleural fluid. The pleurae are responsible for reducing the amount of friction that occurs between the lungs and the chest wall when respiratory function is being performed. All of the lungs are composed of lobes, with the right lung having three lobes and the left lung having two lobes. With millions of alveoli dispersed throughout the lungs, the anatomy of the lungs is designed to optimize the surface area available for gas exchange.

Movement of the Diaphragm and the Breathing Mechanism The diaphragm, which is a dome-shaped muscle that is situated behind the lungs, is an essential component of the breathing mechanism. Inhalation causes the diaphragm to contract and travel downward, which results in the creation of a negative pressure within the thoracic cavity. This pressure causes air to be drawn into the lungs that are there. Air is expelled from the lungs as a result of the diaphragm relaxing and moving higher during the exhalation process. This process is frequently reinforced by auxiliary muscles, such as those in the chest and belly, particularly while engaging in strenuous activities or experiencing respiratory trouble.

Regulation of the Respiratory System The respiratory system is regulated by systems that are both voluntary and involuntary. The basic rhythm of breathing is controlled by the medulla oblongata and the pons, which are located in the brainstem. These structures respond to variations in the amounts of carbon dioxide and pH in the blood. Chemoreceptors, which are found in the blood vessels and the brain, are responsible for monitoring these changes and adjusting the pace and depth of breathing at such times. Furthermore, higher brain areas have the ability to modify respiratory patterns in response to deliberate behaviors, such as singing or speaking.

The capacity of the respiratory system to exchange gases in an effective manner is absolutely necessary for the maintenance of life. In addition to having a significant impact on respiratory function and overall health, conditions that affect any portion of this system, such as chronic obstructive pulmonary disease (COPD), asthma, or pneumonia, can also have an effect on the respiratory system. Through the process of diagnosing, treating, and managing respiratory

diseases, which eventually leads to improved patient outcomes and quality of life, it is helpful to have a comprehensive understanding of the intricate anatomy and function of the respiratory system.

2.2.1 Asthma

There is a chronic inflammatory illness of the airways known as asthma. This disease is defined by the intermittent and reversible restriction of airflow, which results in difficulties breathing. Wheezing, chest tightness, shortness of breath, and coughing are some of the symptoms that are associated with this condition. The frequency and degree of these symptoms might vary. The condition known as asthma affects millions of individuals all over the world and, if not adequately controlled, can have a substantial influence on the quality of life of an individual.




Figure 8: Asthma

The pathophysiology of asthma is characterized by a continuous inflammation of the bronchial tubes, which results in the airways being enlarged and overly sensitive. This is the fundamental pathophysiology of asthma. This inflammation causes an increase in the production of mucus as well as a constriction of the smooth muscle that surrounds the airways, which ultimately results in the airways becoming narrower and requiring less air to pass through them. The inflamed airways become even more reactive in response to a variety of stimuli, such as allergens, respiratory infections, or environmental irritants, which ultimately results in acute

asthma attacks. The symptoms are made worse by bronchoconstriction, which further narrows the airways and makes it difficult to breathe. This occurs during an attack.

In addition to being triggered by a wide range of environmental and genetic factors, asthma can also be triggered by a number of risk factors. Some of the most common allergens that can set off an allergic reaction are pollen, mold, pet dander, and dust mites. Other irritants that can set off an allergic reaction include tobacco smoke, air pollution, strong scents, and cold air. In addition, respiratory illnesses, particularly viral infections such as the common cold, have the potential to compound the symptoms of asthma. There is also the possibility that exercise-induced asthma could be triggered by physical exertion, particularly when the weather is dry or cold. Some of the variables that can increase the likelihood of acquiring asthma are having a family history of the condition, being exposed to allergens in the environment, and having a history of atopic conditions like eczema or allergic rhinitis.

A combination of clinical evaluation, patient history, and diagnostic testing are required in order to arrive at a diagnosis of asthma. When trying to uncover patterns of symptoms and potential triggers, it is necessary to have a comprehensive medical history. The evaluation of airway obstruction and reversibility is typically accomplished by the utilization of pulmonary function tests, such as spirometry. The amount of air that is exhaled as well as the rate at which it is exhaled are both measured by spirometry, which ultimately provides information on the degree to which airflow is restricted. Further, peak flow monitoring can be utilized to assist in tracking changes in lung function over the course of time. There are some instances in which further tests, such as bronchoprovocation tests or allergy testing, could be carried out in order to identify particular triggers and ultimately direct treatment.

In order to effectively manage asthma, it is necessary to employ both pharmacologic and non-pharmacologic approaches. These approaches are aimed at reducing the severity of symptoms and avoiding exacerbations. Long-term management relies heavily on inhaled corticosteroids because of their ability to significantly reduce inflammation and avoid the development of chronic symptoms. In order to offer more bronchodilation and to treat symptoms that are chronic, long-acting beta-agonists may be administered in concert with corticosteroids. Short-acting beta-agonists are an effective method for providing rapid relief since they instantly relax the muscles of the airway and reduce symptoms. Identification and avoidance of asthma triggers, utilization of peak flow meters for the purpose of monitoring lung function, and adherence to an asthma action plan prepared in collaboration with a healthcare professional are

also components of asthma management. The importance of education regarding the correct use of inhalers and the adherence to prescribed drugs cannot be overstated in terms of effective management.

If they receive the appropriate therapy and make the necessary adaptations to their lifestyle, the majority of people who suffer with asthma are able to achieve good control of their symptoms and enjoy lives that are both active and healthy. It is critical to regularly follow up with healthcare specialists so that treatment regimens can be adjusted as needed and problems can be monitored. Asthma management is a continuous process that requires patients and healthcare providers to work together for the best possible outcome in terms of the patient's respiratory health in the long run.

2.2.2 Chronic Obstructive Airways Diseases

The term "chronic obstructive airways diseases" refers to a collection of progressive respiratory conditions that are defined by persistent airflow limitation and chronic inflammation of the airways. Both chronic bronchitis and chronic obstructive lung disease (also known as COPD) are among the most prevalent illnesses that fall within this group. In addition to having a substantial impact on the overall lung function and quality of life, these diseases are responsible for a significant amount of morbidity and death across the globe.

Chronic Obstructive Pulmonary Disease (COPD) is a significant chronic respiratory condition that is defined by persistent airflow obstruction that is not totally reversible. COPD is recognized as a major respiratory condition. Long-term exposure to hazardous particles or gasses is often the cause of this condition, with cigarette smoking being the most major risk factor. The acronym COPD is an umbrella term that encompasses both chronic bronchitis and emphysema, which frequently occur together. Chronic inflammation of the airways and lung parenchyma is a pathogenesis of chronic obstructive pulmonary disease (COPD). This inflammation causes structural changes in the lungs, including remodeling of the airways and loss of the alveolar walls. Lung function gradually deteriorates as a consequence of this, and symptoms such as continuous coughing, production of sputum, and shortness of breath are some of the symptoms that manifest. The condition worsens over time and can result in considerable restrictions on one's ability to engage in physical activity as well as a loss of quality of life.

Chronic Bronchitis: Chronic bronchitis is characterized by a cough that is productive and continues for a minimum of three months throughout the course of two years in any given year. The chronic inflammation of the bronchial tubes, which causes an excessive amount of mucus to be produced and a continuous cough, is the defining characteristic of this condition. Because of the inflammation and the creation of mucus, the airways become obstructed, which results in a reduction in airflow and an increase in the likelihood of respiratory infections. Patients who have chronic bronchitis frequently encounter symptoms such as wheezing, dyspnea (shortness of breath), and a persistent cough that produces sputum that is thick and brownish. There is a strong correlation between chronic bronchitis and smoking for an extended period of time as well as exposure to environmental contaminants. Reducing symptoms, preventing exacerbations, and improving quality of life are the primary goals of management. This can be accomplished through quitting smoking, using medications, and making changes to everyday lifestyle.

Emphysema is a part of COPD that is characterized by the degradation of the alveoli, the tiny air sacs in the lungs that are responsible for gas exchange. There is less surface area available for gas exchange due to the loss of alveolar walls. This makes it harder to exhale, which in turn causes air to get trapped. In most cases, the damage to the alveoli is brought on by prolonged exposure to smoking or toxins in the environment. One of the symptoms of emphysema is a decreased tolerance for physical activity, along with shortness of breath and a persistent cough. Individuals who have the disease may have a chest that is shaped like a barrel as the disease progresses because of the overinflation of the lungs. Eliminating symptoms, enhancing lung function, and preventing additional damage are the primary goals of emphysema management. This can be accomplished through quitting smoking, using specific drugs, and participating in pulmonary rehabilitation.

Diagnosis and Management: The process of diagnosing chronic obstructive airways diseases requires a thorough review that takes into account the patient's medical history, clinical symptoms, and diagnostic tests. Spirometry is an important diagnostic tool that measures the volume and speed of airflow in order to determine the degree of interference that is present. Diagnostic imaging procedures, such as computed tomography (CT) scans or chest X-rays, can be utilized to assist in the visualization of structural alterations in the lungs. These disorders are managed with the goals of reducing the severity of symptoms, enhancing quality of life, and slowing the development of the disease. In most cases, this entails the utilization of pharmacologic treatments like bronchodilators and inhaled corticosteroids, as well as the

withdrawal from smoking and the participation in pulmonary rehabilitation. In addition, patients may benefit from receiving immunizations and supplemental oxygen therapy in order to prevent contracts of respiratory illnesses. Regular monitoring, adaptations to one's lifestyle, and strict adherence to treatment programs are all necessary components of long-term therapy in order to achieve optimal respiratory health and effectively manage chronic symptoms.

Prognosis and Quality of Life: The prognosis of chronic obstructive airways disorders varies based on the severity of the ailment, the presence of comorbidities, and the success of treatment. Quality of life is also affected positively by the prognosis. Early diagnosis and comprehensive care can greatly reduce symptoms, decrease the advancement of the disease, and boost quality of life, despite the fact that many diseases are progressive and there is presently no cure for them. Patients who suffer from chronic obstructive airways diseases frequently experience a decline in their physical function and overall well-being. Because of this, it is essential to address both the physical and emotional aspects of the disease through a multidisciplinary approach that includes healthcare providers, caregivers, and support networks.

2.3 Renal system

The renal system, often called the urine system, functions as an integral part of the body's homeostatic systems. The kidneys are in charge of regulating blood pressure, flushing out waste, and keeping fluid and electrolyte levels stable. This system is comprised of the ureters, kidneys, bladder, and urethra. The filtration, storage, and evacuation of urine are facilitated by each of these organs to varying degrees.




Figure 9: Renal system

➤ **The kidneys**

Kidneys are two bean-shaped organs that are necessary for maintaining overall homeostasis within the body. They are located in the lower back, right behind the rib cage, and are located in the lower back. In order to remove waste products, excess chemicals, and toxins from the blood, each kidney performs an essential function in the process of filtering the blood. These toxins are subsequently eliminated through the creation of urine. In order to maintain a variety of physiological processes and to guarantee that the internal environment continues to be stable and balanced, this filtration process is essential.

Nephrons are the functional units of the kidney, and each kidney contains roughly one million nephrons. Nephrons are necessary for renal function. The glomerulus and a series of tubules are the two primary components that together make up each and every nephron. The glomerulus is a network of capillaries that is responsible for the first phase of the filtration process of circulatory blood. At this point, the pressure of the blood pushes water and other tiny solutes past the walls of the capillaries and into the capsule that surrounds them, resulting in the formation of a filtrate that will later become urine. Following this, the filtrate is transported via a convoluted network of tubules, which is where the processes of reabsorption and secretion

take place. Tubules are responsible for the selective reabsorption of important nutrients, electrolytes, and water back into the bloodstream. At the same time, they secrete waste materials and surplus substances into the tubular fluid for elimination.

The kidneys play a crucial role in the body by regulating the levels of electrolytes such as calcium, potassium, and sodium. This is achieved by processes that help keep the body's acid-base balance in check, such as the reabsorption of bicarbonate and the excretion of hydrogen ions. Ensuring that these electrolyte concentrations stay within appropriate values is the kidneys' job. For the body's general well-being and for a number of cellular processes, this is crucial.

The kidneys regulate blood pressure and keep electrolyte levels stable through a mechanism called the renin-angiotensin-aldosterone system (RAAS). The kidneys secrete renin, an enzyme that sets in motion a cascade of reactions that culminates in the production of angiotensin II, while the blood pressure keeps dropping. Because of its potent vasoconstrictive effects, angiotensin II raises blood pressure by narrowing blood arteries. This chemical also stimulates the adrenal glands to release more aldosterone, which has an additional consequence. Aldosterone causes an increase in blood volume and, by extension, blood pressure, by stimulating the reabsorption of salt and water by the kidneys. Because it aids in maintaining a normal blood pressure range, this technique is particularly useful in situations involving blood loss or dehydration.

Also, the hormone erythropoietin is essential for the production of red blood cells, and its manufacture is the responsibility of the kidneys. As a defense mechanism against hypoxia, the body produces erythropoietin, which stimulates the bone marrow to produce more RBCs. An increase in the quantity of red blood cells in the bloodstream improves the transport of oxygen to tissues all throughout the body by increasing the blood's capacity to carry oxygen.




Figure 10: Kidney

➤ **Ureters (plural)**

Urine is transported from the kidneys to the bladder via the ureters, which are two tubes that are relatively small. It is estimated that each ureter is between 25 and 30 centimeters in length and is lined with smooth muscle tissue. This tissue contracts in a rhythmic manner to force urine downward through the process of peristalsis. Vesicoureteral reflux is a condition that occurs when the ureters enter the bladder at an angle, which results in the formation of a valve-like mechanism that stops urine from flowing backward against the bladder. In order to ensure that urine travels smoothly from the kidneys to the bladder without creating obstruction or infection, it is vital that the ureters work properly.




Figure 11: Ureters (plural)

➤ **The Bladder**

The bladder is a muscular organ that is placed in the pelvis and holds urine in a temporary storage location. It is hollow and has a muscular structure. It is able to expand to accept different amounts of pee, and its typical capacity ranges from approximately 400 to 600 milliliters. The transitional epithelium that lines the bladder wall is able to stretch as the bladder fills so that it can accommodate the expanding bladder. During the process of urination, the detrusor muscle, which is the primary muscle of the bladder, contracts in order to release pee. Internal and external sphincters are also present in the bladder, and they are responsible for controlling the flow of urine. The internal sphincter is composed of smooth muscle and is controlled involuntarily, whereas the external sphincter is composed of skeletal muscle and is controlled deliberately. This allows for the conscious control of urine.




Figure 12: Bladder

The bladder is an important muscle organ that is situated in the pelvis. Its major function is to act as a storage reservoir for urine before it is discharged from the body. Its structure is designed to accommodate different amounts of urine, displaying extraordinary flexibility and resilience in its construction. The bladder has the capacity to contain between 400 and 600 milliliters of pee, although the amount of urine that it can hold can vary from person to person. It is vital for the bladder to be able to expand and contract in order for it to perform its role, and the bladder's flexible nature is made possible by the distinctive anatomical and physiological properties that it possesses.

Because of its ability to expand and handle growing amounts of urine, the bladder is lined with a specific type of epithelium known as transitional epithelium. This epithelium is essential for the bladder's proper functioning. The ability of this epithelium to change shape and form as the bladder fills and empties is what makes it stand out from another epithelium. When the bladder is empty, the transitional epithelium appears to be composed of multiple layers of cells. However, as the bladder fills up and expands, these cells become more flattened, which enables the bladder wall to stretch without breaking. This adaptability is essential for the function of the bladder because it enables the bladder to deal with the varying amounts of pee that are produced throughout the different hours of the day.

When it comes to the process of urination, the detrusor muscle, which is a layer of smooth muscle that surrounds the bladder, is very important. During the filling phase, the detrusor muscle does not contract, which enables the bladder to expand and accept the growing amount of pee that is being produced. Expulsion of urine from the bladder is accomplished through the coordinated contraction of the detrusor muscle, which occurs when it is time to urinate. This contraction is caused by signals from the neurological system, more notably from the parasympathetic nervous system, which is responsible for initiating the procedure known as the micturition reflex.

Internal and external sphincters, which are located near the outflow of the bladder, are responsible for controlling the quantity of pee that is expelled. The smooth muscle that makes up the internal sphincter is under involuntary control, which means that it naturally functions without any conscious action on the part of the individual. By keeping urine from leaking out of the bladder when it is not acceptable to pee, this sphincter contributes to the maintenance of continence. On the other hand, the external sphincter is composed of skeletal muscle and is controlled by the individual voluntarily. By allowing humans to deliberately manage the time of urination, this sphincter gives people the opportunity to commence or delay peeing dependent on the social or situational appropriateness of the scenario.

When it comes to regular urine function, the synchronization that occurs between the detrusor muscle and the sphincters is absolutely necessary. When the bladder is full of pee, stretch receptors in the wall of the bladder send signals to the brain that indicate the urge to urinate. Because of this, the brain sends signals to the detrusor muscle, which causes it to contract, and to the sphincters, which causes them to relax. This makes it possible for urine to flow from the bladder via the urethra and out of the body. For the purpose of preventing urine incontinence or retention, it is necessary to carefully regulate this process in order to guarantee that the bladder is completely eliminated.

➤ **Urethra (a)**

There is a tube called the urethra that is responsible for transporting urine from the bladder to the outside of the body. In males, it is roughly twenty centimeters in length and also functions as a conduit for sperm during the process of ejaculating. The length of this structure varies depending on the gender. The length of the urethra in females is around four centimeters, and it is situated directly in front of the vagina. In addition to an internal sphincter that helps regulate the flow of urine, the urethra also has an external sphincter that enables the individual

to exercise voluntary control over the act of urinating. For the purpose of preventing urinary tract infections and ensuring that urine is completely expelled from the body, it is essential that the urethra performs its functions correctly.

The urinary system is comprised of several essential components, one of which is the urethra, which functions as the passageway by which urine is expelled from the body from the bladder. The length and function of this tubular structure differ greatly between males and females, which is a reflection of the structure's adaptation to the anatomical and physiological variances that exist between their respective genders.




Figure 13: Urethra (a)

The urethra is roughly twenty centimeters in length and serves two purposes in males. Its length is around twenty centimeters. Not only does it make it easier for urine to be expelled from the bladder, but it also acts as a passageway for sperm during ejaculating. The urethra can carry out two tasks at once because it connects the prostate gland to the penis and opens at the tip of the glans. The male urethra is composed of many parts. There are three parts to the urethra: the penile or spongy urethra, which extends into the penis, the short membranous urethra that passes through the pelvic floor, and the prostatic urethra, which is located in the prostate gland. The intricate and lengthy male urethra has a dual purpose, contributing to both urination and reproduction. This system is exceptionally important in male physiology.

The female urethra, on the other hand, is substantially shorter than the male urethra, measuring approximately four centimeters in length. Anatomically speaking, it is situated in front of the

vagina, and it extends from the bladder to an external orifice that is situated immediately above the vaginal entrance. Because the female urethra is just responsible for transporting pee and does not play any role in reproduction, its length is shorter than that of the male urethra. Both an internal and an exterior sphincter are present in the female urethra, despite the fact that it is typically shorter than the male urethra. With its location at the point where the urethra and the bladder meet, the internal sphincter is the organ that is accountable for the involuntary regulation of the flow of pee. It is the external sphincter, which is situated further down the urethra, that is responsible for providing voluntary control, which enables individuals to control the timing of urination and the initiation of it.

With regard to the maintenance of urinary continence and the prevention of leaks, the internal and external sphincters both play critically important functions. On the other hand, the external sphincter enables voluntary control, which is essential for both social and functional purposes. The major function of the internal sphincter is to prevent the involuntary flow of urine. For the purpose of preventing urinary tract infections (UTIs) and ensuring that urine is discharged in a manner that is both complete and effective, it is crucial that these sphincters operate correctly.

If the defensive systems of the urethra are impaired, it is more likely that bacteria will ascend the urethra and reach the bladder, which can lead to the development of urinary tract infections (UTIs). Because the urethra is shorter in females, it is simpler for bacteria to enter the bladder. This is the reason why urinary tract infections (UTIs) are more prevalent in females. Both men and women should make it a priority to practice good urethral hygiene and function in order to reduce the risk of urinary tract infections and to preserve overall urinary health.

In general, the roles that the urethra plays in the transportation of pee, the structural differences that exist between the sexes, and the control mechanisms that it possesses are essential to its function in both urinary and reproductive health. It is crucial for the urethra to work properly in order to maintain the homeostasis of the body and to prevent infections; hence, it is an important component of the urinary system.

➤ **Disorders and Functions of the Body**

A number of essential processes are carried out by the renal system. These duties include the filtration of blood in order to remove waste products such as urea, creatinine, and uric acid; the regulation of fluid and electrolyte balance; the regulation of acid-base balance; and the

regulation of blood pressure. In addition, the kidneys are involved in the generation of hormones, which are essential for the activities that are being discussed.

Renal system disorders can have a significant impact on health and include conditions such as chronic kidney disease (CKD), which is characterized by a gradual loss of kidney function over time, and acute kidney injury (AKI), which is characterized by a sudden decline in kidney function due to a variety of causes including dehydration, infections, or toxins. Both of these conditions are examples of conditions that can influence health. UTIs, which are infections of the urinary tract, can affect any component of the urinary system. However, due to anatomical variations, urinary tract infections are more common in females. Mineral and salt deposits that are solid and form in the kidneys are known as kidney stones. These stones can cause significant pain and obstruction of the urinary tract. Managing these conditions typically entails receiving medical care, making adjustments to one's way of life, and, in more severe circumstances, undergoing interventions such as kidney transplantation or dialysis.

In a nutshell, the renal system is vital for the maintenance of homeostasis in the body since it is responsible for managing the balance of fluids and electrolytes, getting rid of waste, and controlling blood pressure. Each individual part of the system—the kidneys, the ureters, the bladder, and the urethra—is responsible for a distinct function in order to guarantee the efficient filtration and elimination of urine throughout the body. When it comes to overall health and the avoidance of diseases related to the kidneys, it is essential to have a solid understanding of the renal system and to take care of its health.

2.3.1 Acute and chronic renal failure

Both acute renal failure (ARF) and chronic renal failure (CRF), which are often referred to as acute kidney injury (AKI) and chronic kidney disease (CKD), respectively, are serious illnesses that compromise kidney function. Each of these conditions has a unique set of causes, manifestations, and approaches to treatment.

❖ Acute Renal Failure (ARF)

Acute kidney injury, also known as acute renal failure, is characterized by a fast and rapid reduction in kidney function that can take place over a period of time ranging from hours to days. It is defined by a severe loss in the kidneys' ability to filter waste products from the blood, which leads to a buildup of toxins, electrolyte imbalances, and fluid overload. This condition is common in those who have chronic renal disease. In the event that the problem is detected

and treated in a timely manner, it is frequently reversible; nevertheless, if it is not managed successfully, it can result in serious consequences and long-term damage to the kidneys.




Figure 14: Acute Renal Failure (ARF)

Origins: ARF can be caused by a wide variety of underlying reasons, which can be broken down into three primary categories:

There are a number of underlying disorders that can lead to acute renal failure (ARF), which is now more often known as acute kidney injury (AKI). These conditions can bring about kidney function being compromised. Prerenal, intrinsic renal, and postrenal causes are the three primary categories that are commonly used to classify these causative factors. On the other hand, each kind is associated with a unique set of pathophysiological mechanisms and management and therapy implications.

❖ Causes of the Prerenal System

Prerenal acute kidney injury (AKI) is caused by a decrease in the amount of blood that flows to the kidneys, which hinders the kidneys' capacity to filter blood properly. This particular form of acute kidney injury (AKI) is frequently associated with diseases that result in systemic hypoperfusion, which is a condition in which the kidneys receive insufficient blood flow despite their normal structural integrity. Severe dehydration, heart failure, and shock are all common causes of this condition.

Extreme dehydration occurs when fluids are lost as a result of vomiting, diarrhea, or extreme perspiration. This can result in a drop in blood volume and a reduction in the amount of blood that makes its way to the kidneys. In reaction to a decrease in blood supply, the kidneys may have difficulty performing their filtering activities properly, which can result in an increase in the levels of serum creatinine and blood urea nitrogen (BUN).

Heart failure is characterized by a decrease in the perfusion pressure that is applied to numerous organs, including the kidneys. This is because the heart is unable to pump blood effectively, which leads to heart failure. It is possible for this decreased perfusion to lead to prerenal acute kidney injury (AKI), which occurs when the kidneys do not receive enough blood to perform their usual filtering role.

There are several types of shock, including septic shock, hypovolemic shock, and cardiogenic shock. All of these types of shock entail a significant decrease in blood flow and pressure, which ultimately results in reduced kidney perfusion. In order to prevent irreversible kidney damage, it is vital to begin therapy as soon as possible in order to restore blood flow and rectify the underlying reasons.

If the underlying cause is swiftly addressed and normal blood supply to the kidneys is restored, prerenal acute kidney injury (AKI) almost always has the potential to be reversed. Treatment often consists of administering drugs to enhance heart function, administering fluids to resuscitate the patient, or employing treatments to rectify shock.

❖ Renal Causes That Are Intrinsic

Direct damage to the kidney tissues is the cause of intrinsic renal acute kidney injury (AKI), which ultimately results in reduced renal function. The glomeruli, tubules, and interstitial tissues have the potential to be affected by this injury, which can also impact other regions of the kidney. The acute glomerulonephritis, acute tubular necrosis (ATN), and nephrotoxic effects caused by drugs or chemicals are examples of common disorders that affect the kidneys that are intrinsic factors.

Acute Glomerulonephritis is a disorder that is characterized by inflammation of the glomeruli, which are parts of the kidneys that are responsible for filtering blood. This condition may be brought on by infections, autoimmune illnesses, or other events that cause damage to the glomeruli that is mediated by the immune system. It is because of this inflammation that filtration is impeded, proteinuria and hematuria are produced, and kidney function is decreased.

Acute tubular necrosis (ATN) is a condition that is defined by the death of renal tubular cells. This condition is frequently brought on by prolonged ischemia (for example, following major surgery or trauma) or exposure to nephrotoxins, such as certain antibiotics or contrast chemicals that are used in imaging examinations. Tubular cells that have been destroyed make it more difficult for the kidney to reabsorb nutrients that are vital to the body and to eliminate waste items.

Nephrotoxic Medications: Many drugs and chemicals have the potential to cause direct harm to kidney tissues, which can result in acute kidney injury (AKI). NSAIDs, which are nonsteroidal anti-inflammatory medicines, are an example. Other examples include some antibiotics and contrast dyes that are utilized in imaging techniques. The risk of nephrotoxicity can be reduced by monitoring and changing the dosage of medications that are being taken.

Identification and treatment of the underlying cause, discontinuation of nephrotoxic drugs, and provision of supportive care for the kidneys are all critical components in the management of intrinsic renal acute kidney injury (AKI). It is possible that the damage can be reversed in certain instances; nevertheless, prompt intervention is essential in order to limit the long-term renal impairment.

❖ The Causes of Postrenal

Because of the restriction of urine flow anywhere in the urinary system, postrenal acute kidney injury (AKI) occurs. This obstruction causes a rise in pressure within the renal pelvis, which in turn causes damage to the kidney tissues. It is possible for the obstruction to take place in a number of different locations, such as the kidneys, ureters, bladder, or urethra.

Stones that form in the kidneys have the potential to move and obstruct the ureters, which in turn impedes the passage of urine from the kidneys to the bladder after they have formed. The obstruction causes a rise in pressure within the kidneys, which can result in renal damage and acute kidney injury (AKI) if it is not addressed rapidly.

Postrenal acute kidney injury (AKI) can be caused by tumors that are located within the urinary tract. These tumors can be found in the bladder, prostate, or urethra, and they can restrict the flow of urine. It is possible for tumors to penetrate or compress the urinary system, which can result in obstruction and pressure accumulation.

Men who have benign prostatic hyperplasia (BPH) or prostate cancer may experience urinary blockage as a result of the urethra being compressed. This condition is known as enlarged prostate. As a consequence of this obstruction, the flow of urine is hindered, and the pressure in the kidneys and bladder is elevated.

Relieving the obstruction in order to restore normal urine flow and pressure is the primary focus of treatment for postrenal acute kidney injury (AKI). Surgical intervention, the insertion of a urinary stent, or other procedures may be necessary in order to ease the obstruction and prevent additional damage to the kidneys.

In order to facilitate accurate diagnosis, treatment, and management of ARF/AKI, it is essential to have a solid understanding of the various causes and mechanisms that contribute to the condition. Improvements in outcomes and a reduction in the risk of kidney damage over the long term can be achieved through timely intervention and management measures that are appropriate.

❖ Symptoms

Symptoms: Acute Renal Failure (ARF), which is now more generally known as Acute Kidney Injury (AKI), is characterized by a variety of symptoms that are indicative of an abrupt loss in kidney function. One of the most prominent symptoms is oliguria, which is defined as a decrease in the amount of urine that is produced on a daily basis to less than 400 milliliters. Anuria, which is defined as the entire absence of urine flow, may occur in certain instances. Modifications in urine production like these may be an indication of serious renal failure. Patients diagnosed with acute kidney injury (AKI) may also have swelling in the legs, ankles, or other regions of the body as a consequence of fluid retention. This is because the kidneys are unable to drain excess fluids as a result of the condition. To add insult to injury, the accumulation of toxins in the bloodstream that the kidneys ordinarily filter out might also result in altered mental status or confusion. It is possible that pulmonary edema, a disease in which fluid leaks into the lungs, is the cause of shortness of breath. This condition makes breathing difficulties much more difficult. In light of the fact that these symptoms collectively point to a considerable decrease in renal function, it is imperative that a speedy medical evaluation be performed.

The diagnosis of acute kidney injury (AKI) is accomplished using a series of laboratory tests, urinalysis, and imaging examinations. These procedures are used to determine the degree of

kidney damage and to identify potential causes. The levels of serum creatinine are an important indication since increasing levels signal that renal function is becoming less effective. In a similar manner, acute kidney injury (AKI) can result in increased levels of blood urea nitrogen (BUN), which indicates decreased renal clearance of urea. Urinalysis is a diagnostic procedure that helps determine the concentration of the urine, the presence of proteins, and any other abnormalities that may be present. This evaluation can provide light on the underlying cause of the kidney injury. In the case of the presence of casts or cells in the urine, for instance, this may indicate the presence of intrinsic renal causes. During imaging examinations, such as an ultrasound, the kidneys and urinary system are visualized in order to identify any structural abnormalities, blockages, or symptoms of acute inflammation that may be present. These diagnostic techniques assist in determining the type of acute kidney injury (AKI) and guides treatment choices that are appropriate.

❖ Treatment and Management

The treatment for acute renal failure (ARF) focuses on resolving the underlying cause of the condition, promoting kidney function, and preventing complications from occurring. The strategy to treatment is multidimensional and individualized to the particular kind and degree of acute kidney injury (AKI).

Fluid Resuscitation: In situations where acute kidney injury (AKI) is caused by prerenal factors, such as hypovolemia brought on by shock or dehydration, it is essential to deliver fluids to the patient. Maintaining a sufficient blood supply to the kidneys and enhancing their function can be accomplished through the administration of intravenous fluids. This is typically accomplished through the administration of isotonic saline or other fluids, depending on the condition of the patient and the nature of the underlying causes.

Nephrotoxic Medication Discontinuation In the event that acute kidney injury (AKI) is a result of the administration of nephrotoxic medications, such as specific antibiotics or contrast agents, it is of the utmost importance to withdraw these medications as soon as possible. One should take into consideration the possibility of using different medications or dosages that are less damaging to the kidneys.

Elimination of Urinary Obstructions: In cases when acute kidney injury is caused by postrenal factors, it is essential to remove the obstruction. In order to alleviate pressure in the urinary tract, this may entail additional treatments such as surgical intervention, the insertion of a

ureteral stent, or other operations. The removal of the obstruction enables the flow of urine to be unimpeded and prevents the kidneys from suffering any additional harm.

Supportive Measures: Dialysis may be necessary in severe cases of acute kidney injury (AKI) if kidney function is severely damaged. Through the process of dialysis, waste materials and excess fluids are removed from the bloodstream, which helps compensate for the kidneys' decreased capacity to filter blood. Dialysis can be broken down into two primary categories: hemodialysis and peritoneal dialysis. Each of these categories has its own set of indications and procedures.

The need for continuous monitoring is absolutely necessary in order to effectively manage acute kidney injury (AKI). In order to avoid consequences such as electrolyte imbalances (for example, hyperkalemia), acid-base disturbances (for example, metabolic acidosis), and fluid overload, it is vital to do routine assessments of the levels of electrolytes, the acid-base balance, and the fluid status. The outcomes of these monitoring sessions are used to inform adjustments to treatment and supportive measures, with the goals of preserving stability and fostering recovery.

A comprehensive approach is required for the treatment and management of acute renal failure and acute kidney injury (ARF/AKI) in order to address the immediate cause, support kidney function, and prevent an increase in consequences. Both early detection and intervention are essential in order to improve results and reduce the amount of long-term damage to the kidneys.

2.3.2 Chronic Renal Failure (CRF)

A persistent and irreversible reduction in kidney function that can take place over the course of months to years is referred to as chronic renal failure, also known as chronic kidney disease (CKD). Contrary to ARF, chronic kidney disease (CKD) develops gradually, and it frequently does not manifest any symptoms until major damage has been done. Long-term damage to the kidneys, which can be caused by a variety of chronic illnesses and risk factors, is the cause of this condition.

Chronic kidney disease, often known as CKD, is a health condition that worsens over time and is characterized by a gradual decline in kidney function. As a result of the fact that the disease is frequently asymptomatic in its early stages, it is essential to identify and treat the underlying causes in order to limit the advancement of the condition and prevent consequences. In the

development of chronic kidney disease (CKD), there are multiple factors that contribute, and each of these factors affects kidney function in a different way.




Figure 15: Chronic Renal Failure (CRF)

A disorder that is characterized by a continuous and progressive deterioration in kidney function that takes place over a period of time ranging from months to years is referred to as chronic renal failure, which is also known as chronic kidney disease (CKD). In contrast to Acute Renal Failure (ARF), which can manifest itself instantaneously as a result of an acute injury to the kidneys, chronic kidney disease (CKD) develops gradually and frequently does not manifest any symptoms until major damage has already been done. Due to the kidneys' ability to adjust for reduced function, which can disguise the early stages of the disease, this sluggish progression is the result of the kidneys' ability to compensate. Toxins and fluid imbalances in the body gradually build up when kidney function declines because the kidneys become less efficient in filtering waste products and excess fluids from the blood. This results in the progressive accumulation of toxins and fluid imbalances in the body.

Long-term damage to the kidneys, which can be caused by a number of different chronic illnesses and risk factors, is frequently the cause of chronic kidney disease. Among the most common causes are diabetes mellitus, which can result in diabetic nephropathy as a consequence of prolonged high blood sugar levels that damage the blood arteries of the kidneys, and hypertension, which can result in chronic damage to the kidney's filtering units as a consequence of sustained high blood pressure. Chronic glomerulonephritis, in which

inflammation of the glomeruli compromises kidney function, and polycystic kidney disease, a hereditary illness defined by the creation of fluid-filled cysts that gradually replace normal kidney tissue, are two additional variables that contribute to the development of kidney disease. By elevating the pressure within the kidneys and causing damage over time, chronic obstructive uropathy, which is caused by obstructions in the urinary tract that have been present for a long time, can also lead to chronic kidney disease (CKD).

During the early stages of chronic kidney disease (CKD), the disease could not exhibit any recognizable symptoms, which makes early detection exceptionally difficult. As a result of the kidneys' ability to compensate for diminished function to a certain extent, the development of symptoms can be delayed. However, when chronic kidney disease (CKD) progresses, symptoms become more noticeable. These symptoms might include persistent fatigue, fluid retention that leads to edema, changes in urine patterns, and finally symptoms related to the accumulation of waste products such as pruritus (itching), nausea, vomiting, and shortness of breath.

Laboratory testing, urinalysis, and imaging investigations are all components that are utilized in the process of diagnosing chronic kidney disease (CKD). It is vital to conduct laboratory tests in order to evaluate kidney function and identify any abnormalities. Some examples of these procedures include serum creatinine and blood urea nitrogen (BUN). It is indicative of poor renal function when these waste products are present in elevated levels. The presence of proteinuria and hematuria, both of which are important indications of kidney impairment, can be determined through urinalysis. Imaging techniques, such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI), are utilized to assess the size, shape, and structure of the kidneys, as well as to discover any obstructions or abnormalities.

The slowing of the course of chronic kidney disease (CKD) and the improvement of patient outcomes are both dependent on early identification and care. Managing the underlying causes is the primary focus of management strategies. For example, managing blood sugar levels in diabetes and controlling blood pressure in hypertension are both examples of management methods. Modifications to the patient's diet, the use of drugs to alleviate symptoms and mitigate consequences, and consistent monitoring of kidney function are all essential components of the care plan. When renal disease has progressed to an advanced stage, it may be required to undergo renal replacement therapy, which may include dialysis or kidney transplantation, in order to preserve kidney function and control the condition. In persons who have chronic

kidney disease (CKD), it is possible to enhance their quality of life and outcomes by addressing the issues listed above and putting suitable interventions into place.

➤ Type 2 Diabetes Mellitus

One of the most common causes of chronic kidney disease is diabetes mellitus. Increased levels of glucose in the blood, which are characteristic of diabetes, can lead to damage to a number of organs, including the kidneys. The principal mechanism of injury is through diabetic nephropathy, which is a condition in which persistent hyperglycemia leads to alterations in the blood arteries and filtration units of the kidneys. Higher levels of blood sugar lead the walls of the glomeruli, which are the filtering units of the kidney, to become thicker, which in turn makes them less effective at filtering waste. As a consequence, this leads to proteinuria, which is defined as the presence of an excessive amount of protein in the urine, and ultimately results in a reduction in kidney function. When it comes to diabetic individuals, it is crucial to manage their blood sugar levels through changes in diet, medicine, and lifestyle in order to prevent or reduce the course of chronic kidney disease (CKD).




Figure 16: Type 2 Diabetes Mellitus

Diabetes mellitus, a condition that is defined by persistent high levels of glucose in the blood, is one of the most prominent causes of chronic kidney disease (CKD), which is a condition that describes renal damage. The persistent hyperglycemia that results from this condition causes a variety of problems, one of which is diabetic nephropathy, which is a significant factor in

kidney damage. The development of diabetic nephropathy is a specific form of kidney disease that occurs as a direct consequence of diabetes. This is mostly owing to the negative impact that elevated blood glucose levels have on kidney function.

Under the condition known as diabetic nephropathy, the kidneys undergo structural and functional alterations over time as a result of elevated blood glucose levels. The glomeruli, which are the principal filtering units of the kidneys, are particularly impacted by this condition. Glomeruli are responsible for filtering waste items out of the blood while preserving important proteins and other molecules. This process occurs under normal settings. On the other hand, when there is a persistently high level of blood sugar, the walls of these glomeruli become thicker and less elastic. Because of this thickening, which is referred to as glomerulosclerosis, the glomeruli are unable to filter blood as efficiently as they once did. Proteinuria is the condition that occurs when proteins that are ordinarily kept in the bloodstream begin to seep into the urine. This condition is characterized by the presence of protein.

Proteinuria is a good early diagnostic of diabetic nephropathy and frequently indicates a decline in kidney function. It is a symptom that can be seen in diabetic patients. Over the course of time, as the illness worsens, the kidneys' capacity to filter waste materials from the blood decreases. This, in turn, causes a steady accumulation of toxins and fluid imbalances within the body. In the case that this trend is not appropriately treated, it can lead to more severe symptoms and problems, such as hypertension, fluid retention, and ultimately end-stage renal disease.

When it comes to persons who have diabetes, the effective management of blood sugar levels is absolutely necessary for preventing or reducing the advancement of chronic renal disease. This requires a multi-pronged strategy, which includes alterations to one's diet in order to restrict the amount of carbohydrates consumed and lower blood glucose levels, the use of drugs such as insulin or oral hypoglycemic agents in order to regulate blood sugar levels, and adjustments to one's lifestyle, such as engaging in regular physical exercise and managing one's weight. In addition, the management of blood pressure and the routine monitoring of kidney function, which includes regular examinations for proteinuria, are both crucial components of therapy.

Through the implementation of these management measures, it is possible to either lessen the likelihood of acquiring diabetic nephropathy or to decrease the advancement of the condition in persons who are already affected by an existing condition. The maintenance of optimal blood glucose levels, in conjunction with regular monitoring and management, is an essential

component in the process of safeguarding renal function and enhancing the overall quality of life for those who are diagnosed with diabetes.

➤ **High blood pressure**

Another significant contributor to chronic kidney disease is hypertension, sometimes known as high blood pressure. Continuous hypertension places an excessive amount of pressure on the blood arteries of the kidneys, which, over time, can cause damage to the kidneys. The kidneys' capacity to filter blood adequately is hindered as a result of the high pressure, which causes changes in the microvascular system of the kidneys. These changes include the thickening and narrowing of the blood vessels. This disorder can directly cause damage to the kidneys and can also make other underlying causes of chronic kidney disease (CKD) worse. For the purpose of limiting the advancement of chronic kidney disease (CKD) and conserving kidney function, it is essential to perform effective treatment of hypertension by lifestyle adjustments, antihypertensive medicines, and regular monitoring.

It is important to note that hypertension, also known as high blood pressure, is a substantial contributor to the development of chronic kidney disease (CKD) and plays a big part in the decline of kidney function. An intricate network of blood arteries is present in the kidneys, which play an essential role in the process of removing waste materials from the bloodstream. Continuous hypertension, on the other hand, causes these blood vessels to be subjected to an excessive amount of pressure, which results in a variety of adverse outcomes.

When high blood pressure is maintained for an extended period of time, it can cause damage to the microvascular system that is found within the kidneys. It is a disorder known as hypertensive nephrosclerosis that causes structural changes in the blood vessels, such as thickening of the vessel walls and constriction of the blood vessels. This damage reveals itself as structural changes in the blood vessels. Because the blood arteries become thicker and more constricted, the amount of blood that flows to the kidney tissues decreases, which hinders the kidneys' capacity to filter blood adequately. The decreased filtration capacity of the kidneys is a significant factor in the progressive course of chronic kidney disease (CKD), which is caused by the impaired blood flow.

Not only does hypertension cause direct damage to the kidneys, but it can also make other underlying causes of chronic kidney disease (CKD) worse. For instance, it is possible for high blood pressure to hasten the advancement of kidney damage in those who already have pre-

existing illnesses such as diabetic nephropathy or glomerulonephritis. There is a vicious cycle that is created when hypertension and other illnesses that damage the kidneys interact with one another. This cycle causes each condition to increase the effects of the other, which ultimately results in a faster decline in kidney function.

For the purpose of preserving kidney function and reducing the progression of chronic kidney disease (CKD), effective management of hypertension is essential. Changing one's lifestyle, receiving pharmacological treatment, and maintaining a regular monitoring schedule are all components of this management strategy. Alterations to one's lifestyle, such as lowering the amount of sodium consumed through food, increasing the amount of physical exercise one engages in, preserving a healthy weight, and avoiding excessive use of alcohol, can assist in the regulation of blood pressure levels.

A common component of pharmacological treatment is the use of antihypertensive drugs. These medications, which include calcium channel blockers, angiotensin II receptor blockers (ARBs), and angiotensin II receptor inhibitors (ACE inhibitors), not only serve to reduce blood pressure but may also offer additional kidney protective advantages. These drugs have the ability to lower the pressure that is present inside the blood arteries of the kidneys, so mitigating the damage that is produced by hypertension.

It is crucial to do routine monitoring of an individual's blood pressure and kidney function in order to guarantee that the treatment continues to be effective and to make any necessary adjustments. Regular monitoring of blood pressure, in conjunction with evaluations of kidney function through laboratory tests and imaging investigations, is beneficial in monitoring the progression of chronic kidney disease (CKD) and in adapting treatment regimens to the specific requirements of each individual client.

It is feasible to effectively regulate blood pressure, decrease the progression of chronic kidney disease (CKD), and improve overall kidney function by managing hypertension through a comprehensive approach that involves adjustments in lifestyle, medication, and continual monitoring. When it comes to lowering the risk of complications and improving the quality of life for those who have chronic renal disease, this proactive care is essential.

➤ **Glomerulonephritis that is chronic**

A persistent inflammation of the glomeruli, which are the small filtering units found within the kidneys, is the defining characteristic of the illness known as chronic glomerulonephritis. This

inflammation may be the result of a number of different reasons, such as autoimmune illnesses, infections, or other processes inside the body that create inflammation. The chronic inflammation causes scarring and fibrosis of the glomeruli, which decreases their capacity to filter waste and ultimately results in gradual damage to the kidneys. In addition to hypertension, hematuria (blood in the urine) and proteinuria are some of the symptoms that may be associated with chronic glomerulonephritis. Management focuses on resolving the underlying cause of the inflammation, managing blood pressure, and using drugs to reduce inflammation and proteinuria. These are the three main components of management.

Consistent inflammation of the glomeruli, which are the minuscule filtering units found within the kidneys, is the defining characteristic of chronic glomerulonephritis, a kidney illness that is both serious and progressive. When urine is produced, the glomeruli are the organs that are responsible for filtering the blood and eliminating waste materials and excess fluids. As a result of these structures becoming inflamed over a lengthy period of time, their capacity to efficiently filter blood is diminished, which ultimately results in slow and frequently irreparable damage to the kidneys. It is possible for a wide range of underlying causes to be the origin of the inflammation that is associated with chronic glomerulonephritis. These underlying causes include autoimmune disorders, infections, and other pathological processes that create inflammatory reactions inside the body.

The start of chronic glomerulonephritis can be ascribed to a number of different reasons, and the pathophysiology of the condition is also known. Systemic lupus erythematosus and IgA nephropathy are two examples of autoimmune disorders. These diseases are characterized by the immune system's erroneous attack on the kidney tissues, which results in persistent inflammation. A similar phenomenon can occur when chronic diseases, such as hepatitis B or C, cause a protracted inflammatory response that affects the glomeruli. In addition, other illnesses, such as diabetes and hypertension, can also contribute to the inflammation and damage that occurs in the glomeruli. Over the course of time, the constant inflammation causes the glomeruli to undergo structural alterations as well as the development of scar tissue, scientifically known as fibrosis. The kidneys' capacity to filter waste products and to maintain fluid and electrolyte balance is impaired as a result of this scarring, which leads to a gradual loss in renal function.

It is possible for the clinical signs of chronic glomerulonephritis to differ from one individual to another depending on the degree of kidney impairment. One of the most common symptoms

is hypertension, which is frequently brought on by fluid retention and a diminished capacity of the kidneys to regulate blood pressure during pregnancy. Because hematuria, also known as the presence of blood in the urine, can cause the urine to have a smokey or reddish appearance, it is an indication that the glomeruli have been damaged. In addition to being an indication of glomerular injury that hinders protein filtration, proteinuria, often known as an excess of protein in the urine, can also cause the urine to become foamy. It is possible for individuals to have generalized edema (swelling) as the disease progresses, notably in the legs, ankles, or around the eyes, as a result of the accumulation of fluid during the course of the disease. Additionally, as kidney function declines, symptoms such as fatigue, nausea, and shortness of breath may occur. These symptoms are a reflection of the accumulation of waste products and fluid imbalances in the body.

Management: The management of chronic glomerulonephritis entails taking a multi-pronged approach with the goals of resolving the underlying source of the inflammation, regulating symptoms, and preventing additional damage to the kidneys. Among the most important aspects of management are the following:

Effective treatment begins with determining and resolving the underlying cause of the glomerular inflammation. This is the first step in the treatment process. It is possible that immunosuppressive medications, such as corticosteroids or other immunomodulatory agents, will be used in the treatment of autoimmune-related glomerulonephritis. These treatments are intended to diminish the inflammatory response. The infection is treated with targeted antibiotics or antiviral drugs in order to minimize inflammation and treat the infection, if the infection is the cause of the condition.

The management of blood pressure is essential in order to avoid more kidney damage from occurring. Hypertension is a common complication of chronic glomerulonephritis, and it must be regulated. Antihypertensive drugs, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), are frequently administered to patients with hypertension. There is a reduction in proteinuria and a reduction in the amount of stress that is placed on the kidneys as a result of these medications, which not only assist control blood pressure but also have renal protective benefits.

Improving the Management of Inflammation and Proteinuria Medication, such as corticosteroids or other anti-inflammatory medicines, may be utilized in order to improve the management of inflammation and proteinuria. Changes in nutrition, such as adopting a diet low

in protein, can also assist in lowering the amount of work that the kidneys have to do and in controlling the amount of protein that is found in the urine. It is also possible that the use of diuretics will be prescribed in order to reduce edema and fluid retention.

When it comes to slowing the advancement of the disease and improving patient outcomes, monitoring and follow-up are extremely important. Regular monitoring of kidney function and continuous management are both essential. This consists of regularly scheduled laboratory testing to evaluate serum creatinine levels as well as urine to determine protein and blood levels. In order to study the anatomy and function of the kidneys, imaging studies may be utilized. Continuous follow-up with healthcare practitioners is necessary in order to make adjustments to treatment regimens, manage problems, and educate patients on how to make changes to their lifestyles that will promote kidney health.

➤ **Disease of the Polycystic Kidneys**

The syndrome known as polycystic kidney disease (PKD) is a hereditary condition that is characterized by the development of cysts in the kidneys that are filled with fluid. As a result of their displacement of normal kidney tissue and disruption of normal renal architecture, these cysts gradually expand and multiply, which ultimately results in a progressive loss of kidney function. A pattern of inheritance known as autosomal dominant or recessive can be used to describe PKD, with autosomal dominant PKD being the more frequent kind. In many cases, the progression of the disease is sluggish, and the symptoms that are associated with it include abdominal pain, hypertension, and kidney stones. In order to effectively manage PKD, it is necessary to regulate symptoms, monitor kidney function, and handle any complications that may arise. Dialysis or kidney transplantation may be necessary for patients who have advanced stages of the disease.




Figure 17: Polycystic Kidneys

Polycystic Kidney Disease, often known as PKD, is a hereditary condition that is characterized by the development of a large number of cysts in the kidneys that are filled with fluid. These cysts are typically spherical in shape and contain a fluid that is either absolutely clear or somewhat hazy. It is the proliferation of the cysts that causes the displacement of normal renal tissue and the disruption of the structure and function of the kidney. This disturbance, which occurs over a period of time, causes a gradual decline in kidney function and has the potential to result in substantial renal impairment. The type of inheritance for Parkinson's disease (PKD) can be either autosomal dominant or autosomal recessive, with autosomal dominant PKD being the more common variety.

Patterns of Inheritance and categories: Parkinson's disease (PKD) can be divided into two primary categories according to the inheritance pattern it exhibits. It is estimated that around 90 percent of all occurrences of Parkinson's disease are caused by the autosomal dominant variant, also known as ADPKD. The symptoms of this type often appear in adulthood, typically between the ages of 30 and 50, and they are characterized by a slow start before they become noticeable. Alterations in the PKD1 or PKD2 genes, which are accountable for the formation and expansion of cysts, are the root cause of adipose tissue polymorphism (ADPKD).

Autosomal Recessive Parkinson's disease (ARPKD), on the other hand, is a less common form of the disease that typically manifests itself during the early childhood or infant years. The condition is caused by mutations in the PKHD1 gene and has a tendency to progress more quickly, which ultimately results in severe renal impairment at an earlier stage.

PKD is characterized by the aberrant proliferation of renal epithelial cells, which ultimately results in the creation of cysts. The symptoms of this condition are also associated with this pathophysiology. The expansion of these cysts causes the surrounding renal tissue and blood vessels to become compressed, which in turn reduces the function of the kidneys. The expansion of cysts can result in a variety of symptoms, one of which is discomfort or pain in the abdomen region. This is because the renal capsule is stretched out as a result of the cysts. Another typical symptom is hypertension, often known as high blood pressure. This condition frequently manifests itself as a result of the activation of the renin-angiotensin-aldosterone system, which is a consequence of the formation of renal cysts. It is also common for people with PKD to experience the formation of kidney stones, which can occur as a consequence of alterations in the content of the urine. Furthermore, as a consequence of the cystic alterations, patients may develop hematuria, which is the presence of blood in the urine, as well as urinary tract infections.

In most cases, imaging investigations, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), or ultrasound, are utilized in the process of diagnosing polycystic kidney disease (PKD). These imaging studies have the ability to disclose the presence of cysts in the kidneys as well as the extent of their presence. In situations when the imaging results are unclear or when the family history shows a hereditary form of the disease, genetic testing may also be employed to confirm the diagnosis. This is especially true in situations where the imaging results are unknown. For the purpose of evaluating kidney function and tracking the evolution of the disease, regular monitoring is absolutely necessary. It is common practice to perform routine measures of serum creatinine and glomerular filtration rate (GFR) in order to assess kidney function. Additionally, blood pressure monitoring is performed in order to effectively control hypertension.

Management and Treatment: The management of chronic kidney disease (PKD) focuses on conserving kidney function, preventing complications, and regulating symptoms through the use of medication. This includes the following:

A key objective is to address symptoms such as stomach discomfort and hypertension. Symptom management is designed to address these symptoms. The therapy of pain may involve the use of analgesics and anti-inflammatory medications, but the management of hypertension may require the use of antihypertensive pharmaceuticals, such as ACE inhibitors or ARBs, which may also provide protection for the kidneys. In addition, patients may be given the recommendation to adhere to a diet reduced in sodium in order to assist in the management of fluid balance and the regulation of blood pressure.

Regular follow-up with healthcare providers is necessary for monitoring kidney function and addressing problems. Supportive care is also an important component of monitoring kidney function. This includes imaging examinations that are performed on a regular basis to examine the growth of cysts and the size of the kidneys, as well as laboratory tests that are performed to evaluate kidney function and identify any signs of deterioration. Patients should also be taught about the need of staying hydrated and avoiding substances that are capable of causing nephrotoxicity.

Procedures for the Management of Complications Urinary tract infections and kidney stones are examples of complications that necessitate quick treatment procedures. The treatment of stones may involve the alleviation of discomfort, the use of drugs that facilitate the passage of stones, or in some instances, the removal of stones or the breaking up of stones. Antibiotics are the most common type of treatment for wound infections.

End-Stage Renal Disease and Renal Replacement Therapy: Dialysis or kidney transplantation may become critical in the advanced stages of chronic kidney disease (CKD), which are characterized by a significant impairment of kidney function. Dialysis is a process that involves the utilization of a machine to carry out the filtering tasks of the kidneys. On the other hand, kidney transplantation offers the possibility of a cure by replacing the kidneys that have been damaged with a healthy donor kidney. Patients with polycystic kidney disease (PKD) who are getting close to the terminal stage of renal illness should collaborate closely with their healthcare team in order to assess the various treatment choices and get ready for renal replacement therapy.

➤ **Uropathy that is chronic and obstructive**

The phrase "chronic obstructive uropathy" refers to an obstruction of the urinary tract that lasts for an extended period of time and can cause damage to the kidneys. Conditions such as kidney

stones, tumors, or an enlarged prostate can lead to obstructions in the urinary tract, which can occur anywhere in the urinary tract, including the kidneys, ureters, bladder, or urethra. Obstructions can also be caused by bladder stones. Because of the obstruction, the pressure in the kidneys increases, which results in hydronephrosis, which is characterized by the swelling of the kidneys as a result of the retention of urine, as well as increasing damage to the kidney tissues. In order to restore normal urine flow and prevent additional kidney damage, the management of chronic obstructive uropathy entails removing the obstruction using medicinal or surgical treatments through the use of medical treatment.

To effectively diagnose chronic kidney disease (CKD) and manage it, it is essential to have a solid understanding of these causes. For the purpose of preserving kidney function and slowing the advancement of the disease, it is vital to address the underlying problems, take control of risk factors, and apply suitable treatment options.

Chronic obstructive uropathy is a condition that is defined by having a blockage in the urinary tract that lasts for an extended period of time and causes considerable damage to the kidneys. There are a number of locations throughout the urinary tract that are susceptible to this obstruction, including the kidneys, ureters, bladder, and urethra. There are a number of potential factors that could lead to the obstruction, including kidney stones, tumors, an enlarged prostate, or stones in the bladder. The regular flow of urine is negatively impacted by each of these disorders, which ultimately results in an increase in pressure within the kidneys. The accumulation of urine leads to a condition known as hydronephrosis, which is characterized by an elevated pressure. This condition causes the kidneys to inflate, which ultimately leads to a breakdown in their function.

The pathophysiology and causes of kidney stones are as follows: kidney stones are one of the most common causes of blockage in the urinary tract. In the kidneys, these solid, crystalline masses can form, and they have the potential to clog the ureters, which would prevent urine from passing through. Both malignant and benign tumors have the potential to impede the urinary system. This can occur either through the physical obstruction of the flow of urine or by the inflammation and constriction of the passageway that they cause. By compressing the urethra and obstructing the flow of urine from the bladder, an enlarged prostate, which is generally observed in men of advanced age, can cause discomfort. There is a possibility that stones in the bladder, which can be formed from pee that has been concentrated, can similarly hinder the flow of urine and create comparable obstructive consequences. Hydronephrosis is a

condition that resulted from each of these disorders, which led to an increase in pressure within the kidneys. Because of the persistently high pressure, the kidney tissues can be damaged over time, which might ultimately result in reduced renal function.

A combination of clinical evaluation and imaging testing is often required in order to arrive at a diagnosis of chronic obstructive uropathy. It is common for patients to report with symptoms such as persistent pain in the lower abdomen, urine frequency, urgency, or trouble urinating. It is possible to determine the location of the obstruction as well as its extent by the use of diagnostic imaging techniques such as ultrasonography, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The identification of hydronephrosis and the evaluation of the enlargement of the kidneys are two areas in which ultrasound is very helpful. Additional diagnostic tests, including as urinalysis and blood tests, may be carried out in order to assess the function of the kidneys and identify any indications of infection or inflammation.

The management of chronic obstructive uropathy focuses on removing the obstruction, restoring normal urine flow, and preventing additional kidney damage. Treatment and management of this condition are also discussed. The underlying reason of the obstruction is relevant to the treatment options that are utilized:

For illnesses such as kidney stones, medical treatment may involve the prescription of medicine to either help dissolve the stones or control the pain associated with them. A number of drugs, including alpha-blockers, can be utilized to assist in the passage of smaller stones and alleviate the symptoms of obstruction. In addition, drugs may be utilized in order to address symptoms of benign prostatic hyperplasia (BPH), which include urine urgency and frequency.

Surgical Interventions: In situations where medicinal care is not sufficient, or if the obstruction is severe, it may be essential to perform surgical intervention. There are a number of procedures that can be carried out, including ureteroscopy, which involves the use of a narrow scope to remove stones or tumors from the ureter, and transurethral resection of the prostate (TURP), which is performed to remove prostate enlargement. In order to alleviate the obstruction, it may also be necessary to undergo surgical excision of tumors or stones from the bladder.

Supportive Measures: It is essential to manage complications such as infections or chronic renal disease that may emerge as a result of prolonged blockage in order to prevent further damage to the kidneys. A regular monitoring of kidney function by blood tests and imaging

investigations is one of the supportive measures that can be taken. Other supportive measures include the management of symptoms and problems with appropriately prescribed drugs.

In the case of chronic obstructive uropathy, the prognosis is mostly determined by the promptness and efficiency of the intervention. Prevention is also an important factor in this regard. Diagnoses and treatments administered at an earlier stage can greatly improve results and help preserve kidney function. The management of risk factors linked with obstruction is one of the preventive steps that may be taken. These risk factors include maintaining a balanced diet in order to prevent kidney stones, performing frequent screenings for disorders that affect the urinary system, and addressing underlying conditions such as benign prostatic hyperplasia.

❖ **Symptoms and Diagnosis of Chronic Kidney Disease (CKD)**

When it comes to symptoms, chronic kidney disease (CKD) frequently develops without any noticeable signs or symptoms, particularly in its early stages, which can make early detection difficult. In its early stages, chronic kidney disease (CKD) may demonstrate no symptoms at all or only moderate, non-specific signs. A general feeling of tiredness and diminished energy is one of the common early indicators of renal disease. This is because the kidneys' decreased ability to filter toxins from the blood leads to a general feeling of fatigue. If the kidneys are unable to properly control fluid balance, then fluid retention may be the cause of swelling in the legs, ankles, or around the eyes. This swelling may also be caused by fluid retention. Alterations in the amount of urine that is produced, such as an increase or reduction in the frequency of urination, can potentially serve as an early indicator of functioning kidneys.

Symptoms grow more noticeable and severe as chronic kidney disease (CKD) progresses. A condition known as pruritus, which is characterized by persistent itching, may occur as a result of the accumulation of waste products and toxins in the blood that the kidneys are no longer able to remove properly. As a consequence of the accumulation of uremic toxins, which have an effect on the gastrointestinal tract, sickness and vomiting may be experienced. The accumulation of fluid in the lungs, also known as pulmonary edema, can cause a variety of symptoms, including shortness of breath and difficulty breathing. Waste items can also cause patients to have a metallic taste in their mouths. This is because waste products have the ability to alter the taste buds.

Laboratory tests, urinalysis, and imaging examinations are used in conjunction with one another to facilitate the diagnosis of chronic kidney disease (CKD). These procedures are used

to examine kidney function and structure. It is essential to conduct laboratory tests in order to evaluate kidney function. The presence of elevated amounts of serum creatinine and blood urea nitrogen (BUN) is a sign that kidney function is impaired. Creatinine is a waste product for the metabolism of muscle, and BUN is a consequence of the metabolism of protein; the kidneys are generally responsible for filtering both of these waste products. A higher amount indicates that the kidneys are not filtering the blood as efficiently as they should be.

It is possible to discover anomalies in the urine that may indicate kidney disease through the use of urinalysis. Proteinuria, which is defined as the presence of an excessive amount of protein in the urine, is a common indication of kidney impairment and is frequently one of the initial symptoms of chronic kidney disease (CKD). It is also possible to detect hematuria, which is the presence of blood in the urine and can be an indication of glomerular damage or other renal problems.

In order to determine the size, shape, and structure of the kidneys, imaging studies such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI) are utilized. In addition to providing information on the kidneys' overall condition, these imaging modalities assist in the detection of any structural abnormalities, such as cysts, tumors, or blockages among other things.

It is essential to include the Glomerular Filtration Rate (GFR) while determining the severity of chronic kidney disease (CKD). The glomerular filtration rate (GFR) is a measurement that determines how efficiently the kidneys filter blood. It is determined by serum creatinine levels, age, gender, and race. There are five stages of chronic kidney disease (CKD), beginning with Stage 1 (normal or high GFR with evidence of kidney damage) and progressing all the way up to Stage 5 (end-stage renal disease), which is characterized by a substantial reduction in GFR, which indicates advanced kidney failure. The development of the disease can be determined and treatment options can be guided by monitoring and assessing the glomerular filtration rate (GFR) over time.

When it comes to chronic kidney disease (CKD), an early diagnosis is absolutely necessary in order to initiate suitable management measures that will successfully address symptoms and reduce the progression of the disease. Both the quality of life and the results for patients can be significantly improved by the implementation of early intervention and routine monitoring.

❖ Treatment and Management

Objectives of Management The basic objectives of Chronic Kidney illness (CKD) management are to delay the progression of the illness, regulate symptoms, and prevent complications related to the disease. A comprehensive approach is required for effective management of chronic kidney disease (CKD). This approach should include addressing the underlying diseases that contribute to CKD, optimizing pharmaceutical regimens, adopting dietary changes, and delivering renal replacement therapies when they are required throughout treatment.

One of the most important aspects of chronic kidney disease (CKD) care is the management of the disorders that contribute to kidney damage. Diabetes and hypertension are two of the most common conditions that lead to kidney damage. It is absolutely necessary for diabetic people to keep their blood sugar levels under strict control. Modifications to one's lifestyle, such as alterations to one's food and participation in regular physical activity, as well as pharmacological therapies, such as insulin or oral hypoglycemic medications, are essential in order to accomplish this goal. The utilization of antihypertensive drugs, particularly those that provide renal protection, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), is essential for the successful management of hypertension. Proteinuria is reduced by these medications, which is effective in reducing the progression of chronic kidney disease (CKD). In addition, these medications assist manage blood pressure.

In addition to controlling blood pressure and blood sugar levels, a number of drugs are utilized in order to treat the symptoms and consequences that are associated with chronic kidney disease (CKD). By increasing the amount of urine that is produced, diuretics can assist in the management of fluid overload, hence lowering edema and hypertension. The management of bone mineral abnormalities, which are common in chronic kidney disease (CKD) due to imbalances in calcium and phosphate, commonly involves the use of phosphate binders and calcium supplements. It is possible to administer erythropoiesis-stimulating drugs, often known as ESAs, in order to treat anemia, which is a common consequence of chronic kidney disease (CKD) that arises from decreased erythropoietin production by the kidneys. When it comes to maintaining electrolyte balance and acid-base homeostasis, medications that manage hyperkalemia (which is characterized by increased potassium levels) and acidosis are also extremely important substances.

Modifications to Diet: Diet is an important factor in the therapy of chronic kidney disease (CKD). Patients are frequently counseled to restrict their consumption of protein in order to diminish the stress placed on the kidneys and to reduce the amount of waste products that are produced. The management of blood pressure and fluid retention can be aided by a diet that is low in salt. It is essential to keep a constant eye on the levels of potassium and phosphate, and it may be required to implement dietary restrictions in order to avoid any imbalances. In more advanced stages of chronic kidney disease (CKD), patients may be required to adhere to a specialized diet that is customized to their particular requirements, frequently under the direction of a renal dietitian.

Renal Replacement Therapy: Renal replacement therapy becomes necessary when chronic kidney disease (CKD) has progressed to more advanced stages, specifically Stage 4 and Stage 5. Hemodialysis and peritoneal dialysis are both types of dialysis, which is the most prevalent type of renal replacement therapy. Through the process of peritoneal dialysis, the lining of the abdominal cavity is used as a filter, whereas hemodialysis includes filtering the blood through a machine that is located outside of the body. Another alternative is kidney transplantation, which has the potential to restore kidney function to a level that is close to normal. However, in order to prevent organ rejection, it is necessary to have a donor kidney that is acceptable and to take immunosuppressive medicine for the rest of one's life.

Continuous Monitoring and the Management of Complications: Continuous monitoring is essential for the effective management of chronic kidney disease (CKD) and the prevention of complications. It is vital to perform routine evaluations of kidney function, including glomerular filtration rate (GFR) and serum creatinine, as well as electrolyte levels and blood pressure. When it comes to enhancing patient outcomes and quality of life, monitoring for consequences such as anemia, bone mineral abnormalities, and cardiovascular disease is absolutely necessary. A multidisciplinary strategy is required for the management of these issues. This approach includes the participation of nephrologists, nutritionists, and other healthcare experts in order to provide comprehensive care.

As a whole, the therapy and management of chronic kidney disease (CKD) call for a specialized and preventative strategy in order to address the underlying causes, control symptoms, and stop more kidney damage from occurring. When it comes to improving the quality of life and optimizing health outcomes for people who have chronic kidney disease (CKD), regular follow-up and coordinated care are essential components.

References

1. Adapa, S., Aeddula, N. R., Konala, V. M., Chenna, A., Naramala, S., Madhira, B. R., ... & Bose, S. (2020). COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. *Journal of clinical medicine research*, 12(5), 276.
2. Adiamah, A., Skorepa, P., Weimann, A., & Lobo, D. N. (2019). The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. *Annals of Surgery*, 270(2), 247-256.
3. Ahmed, M., & Ahmed, S. (2019). Functional, diagnostic and therapeutic aspects of gastrointestinal hormones. *Gastroenterology research*, 12(5), 233.
4. Alam, A., Thelin, E. P., Tajsic, T., Khan, D. Z., Khellaf, A., Patani, R., & Helmy, A. (2020). Cellular infiltration in traumatic brain injury. *Journal of neuroinflammation*, 17, 1-17.
5. Alizadeh, A., Dyck, S. M., & Karimi-Abdolrezaee, S. (2019). Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. *Frontiers in neurology*, 10, 282.
6. Ansari, J., & Gavins, F. N. (2019). Ischemia-reperfusion injury in sickle cell disease: from basics to therapeutics. *The American Journal of Pathology*, 189(4), 706-718.
7. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Ziaieian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 74(10), 1376-1414.
8. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Ziaieian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, 140(11), e596-e646.
9. Ashley, C., & Dunleavy, A. (2018). *The renal drug handbook: the ultimate prescribing guide for renal practitioners*. CRC press.
10. Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., ... & Waltenberger, J. (2022). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology

- (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *European journal of heart failure*, 24(1), 4-131.
11. Bagwe-Parab, S., Yadav, P., Kaur, G., Tuli, H. S., & Buttar, H. S. (2020). Therapeutic applications of human and bovine colostrum in the treatment of gastrointestinal diseases and distinctive cancer types: The current evidence. *Frontiers in Pharmacology*, 11, 01100.
 12. Barros, L. L., Farias, A. Q., & Rezaie, A. (2019). Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. *World journal of gastroenterology*, 25(31), 4414.
 13. Bektas, A., Schurman, S. H., Sen, R., & Ferrucci, L. (2018). Aging, inflammation and the environment. *Experimental gerontology*, 105, 10-18.
 14. Benfaremo, D., Manfredi, L., Luchetti, M. M., & Gabrielli, A. (2018). Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. *Current drug safety*, 13(3), 150-164.
 15. Bennett, C. F., Latorre-Muro, P., & Puigserver, P. (2022). Mechanisms of mitochondrial respiratory adaptation. *Nature Reviews Molecular Cell Biology*, 23(12), 817-835.
 16. Berk, M., Köhler-Forsberg, O., Turner, M., Penninx, B. W., Wrobel, A., Firth, J., ... & Marx, W. (2023). Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. *World Psychiatry*, 22(3), 366-387.
 17. Biver, E., Berenbaum, F., Valdes, A. M., de Carvalho, I. A., Bindels, L. B., Brandi, M. L., ... & Rizzoli, R. (2019). Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). *Ageing research reviews*, 55, 100946.
 18. Black, L. M., Lever, J. M., & Agarwal, A. (2019). Renal inflammation and fibrosis: a double-edged sword. *Journal of Histochemistry & Cytochemistry*, 67(9), 663-681.
 19. Bojar, R. M. (2020). *Manual of perioperative care in adult cardiac surgery*. John Wiley & Sons.
 20. Bonanni, R., Cariatì, I., Tancredi, V., Iundusi, R., Gasbarra, E., & Tarantino, U. (2022). Chronic pain in musculoskeletal diseases: Do you know your enemy?. *Journal of clinical medicine*, 11(9), 2609.
 21. Boothby, I. C., Cohen, J. N., & Rosenblum, M. D. (2020). Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair. *Science immunology*, 5(47), eaaz9631.

22. Calabrese, L. H., Calabrese, C., & Cappelli, L. C. (2018). Rheumatic immune-related adverse events from cancer immunotherapy. *Nature Reviews Rheumatology*, 14(10), 569-579.
23. Carter, P., Lagan, J., Fortune, C., Bhatt, D. L., Vestbo, J., Niven, R., ... & Miller, C. A. (2019). Association of cardiovascular disease with respiratory disease. *Journal of the American College of Cardiology*, 73(17), 2166-2177.
24. Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022). Biomarkers for the diagnosis and management of heart failure. *Heart failure reviews*, 1-19.
25. Chavakis, T., Mitroulis, I., & Hajishengallis, G. (2019). Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. *Nature immunology*, 20(7), 802-811.
26. Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., ... & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6), 7204.
27. Chen, Y., Huang, T., Yu, Z., Yu, Q., Wang, Y., Hu, J. A., ... & Yang, G. (2022). The functions and roles of sestrins in regulating human diseases. *Cellular & Molecular Biology Letters*, 27, 1-24.
28. Cheville, A., Smith, S., Barksdale, T., & Asher, A. (2021). Cancer rehabilitation. *Braddom's Physical Medicine and Rehabilitation*, 568-593.
29. Craig, E., & Cappelli, L. C. (2018). Gastrointestinal and hepatic disease in rheumatoid arthritis. *Rheumatic Disease Clinics*, 44(1), 89-111.
30. Cristina, N. M., & Lucia, D. A. (2021). Nutrition and healthy aging: Prevention and treatment of gastrointestinal diseases. *Nutrients*, 13(12), 4337.
31. Cruz, C. S. D., & Kang, M. J. (2018). Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases. *Mitochondrion*, 41, 37-44.
32. Dainton, M. (2024). Acute kidney injury. *Renal nursing: care and management of people with kidney disease*, 115-131.
33. Dalili, D., Isaac, A., Bazzocchi, A., Åström, G., Bergh, J., Lalam, R., ... & Mansour, R. (2020, December). Interventional techniques for bone and musculoskeletal soft tissue tumors: current practices and future directions-part I. ablation. In *Seminars in Musculoskeletal Radiology* (Vol. 24, No. 06, pp. 692-709). Thieme Medical Publishers, Inc..
34. Damluji, A. A., Forman, D. E., Van Diepen, S., Alexander, K. P., Page, R. L., Hummel, S. L., ... & American Heart Association Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. (2020). Older adults in the cardiac intensive care unit:

- factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. *Circulation*, 141(2), e6-e32.
35. De Ligt, K. M., Heins, M., Verloop, J., Smorenburg, C. H., Korevaar, J. C., & Siesling, S. (2019). Patient-reported health problems and healthcare use after treatment for early-stage breast cancer. *The Breast*, 46, 4-11.
36. Domínguez-Andrés, J., Dos Santos, J. C., Bekkering, S., Mulder, W. J., van der Meer, J. W., Riksen, N. P., ... & Netea, M. G. (2023). Trained immunity: adaptation within innate immune mechanisms. *Physiological reviews*, 103(1), 313-346.
37. Drewes, A. M., Olesen, A. E., Farmer, A. D., Szigethy, E., Rebours, V., & Olesen, S. S. (2020). Gastrointestinal pain. *Nature reviews Disease primers*, 6(1), 1.
38. Dumitru, C., Kabat, A. M., & Maloy, K. J. (2018). Metabolic adaptations of CD4+ T cells in inflammatory disease. *Frontiers in Immunology*, 9, 540.
39. Ekinci, C., Karabork, M., Siriopol, D., Dincer, N., Covic, A., & Kanbay, M. (2018). Effects of volume overload and current techniques for the assessment of fluid status in patients with renal disease. *Blood Purification*, 46(1), 34-47.
40. Elad, S., Zadik, Y., Caton, J. G., & Epstein, J. B. (2019). Oral mucosal changes associated with primary diseases in other body systems. *Periodontology 2000*, 80(1), 28-48.
41. ElHawary, H., Baradaran, A., Abi-Rafeh, J., Vorstenbosch, J., Xu, L., & Efanov, J. I. (2021, August). Bone healing and inflammation: principles of fracture and repair. In *Seminars in plastic surgery* (Vol. 35, No. 03, pp. 198-203). Thieme Medical Publishers, Inc..
42. Elkon, K. B. (2018). Cell death, nucleic acids, and immunity: inflammation beyond the grave. *Arthritis & Rheumatology*, 70(6), 805-816.
43. El-Tallawy, S. N., Nalamasu, R., Salem, G. I., LeQuang, J. A. K., Pergolizzi, J. V., & Christo, P. J. (2021). Management of musculoskeletal pain: an update with emphasis on chronic musculoskeletal pain. *Pain and therapy*, 10, 181-209.
44. Enck, P., & Mazurak, N. (2018). The “Biology-First” Hypothesis: Functional disorders may begin and end with biology—A scoping review. *Neurogastroenterology & Motility*, 30(10), e13394.
45. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up." *Cardiovascular Research* 118, no. 7 (2022): 1618-1666.
46. Felgueiras, H. P., Antunes, J. C., Martins, M. C. L., & Barbosa, M. A. (2018). Fundamentals of protein and cell interactions in biomaterials. In *Peptides and Proteins as Biomaterials for Tissue Regeneration and Repair* (pp. 1-27). Woodhead Publishing.

47. Fisher, L., Fisher, A., & Smith, P. N. (2020). Helicobacter pylori related diseases and osteoporotic fractures (Narrative Review). *Journal of clinical medicine*, 9(10), 3253.
48. Gadiparthi, C., Hans, A., Potts, K., & Ismail, M. K. (2018). Gastrointestinal and hepatic disease in the inflammatory myopathies. *Rheumatic Disease Clinics*, 44(1), 113-129.
49. Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., ... & Branch, K. (2021). Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. *New England journal of medicine*, 385(10), 896-907.
50. Gragnano, A., Negrini, A., Miglioretti, M., & Corbière, M. (2018). Common psychosocial factors predicting return to work after common mental disorders, cardiovascular diseases, and cancers: a review of reviews supporting a cross-disease approach. *Journal of occupational rehabilitation*, 28, 215-231.
51. Gusev, E., & Zhuravleva, Y. (2022). Inflammation: A new look at an old problem. *International Journal of Molecular Sciences*, 23(9), 4596.
52. Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., ... & Obeid, M. (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. *Annals of oncology*, 31(6), 724-744.
53. Healy, L. M., Yaqubi, M., Ludwin, S., & Antel, J. P. (2020). Species differences in immune-mediated CNS tissue injury and repair: A (neuro) inflammatory topic. *Glia*, 68(4), 811-829.
54. Heerspink, H. J., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., ... & Wheeler, D. C. (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. *European heart journal*, 42(13), 1216-1227.
55. Hines, R. L., & Jones, S. B. (Eds.). (2021). *Stoelting's Anesthesia and Co-Existing Disease E-Book: Stoelting's Anesthesia and Co-Existing Disease E-Book*. Elsevier Health Sciences.
56. Hollenberg, S. M., Warner Stevenson, L., Ahmad, T., Amin, V. J., Bozkurt, B., Butler, J., ... & Storrow, A. B. (2019). 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, 74(15), 1966-2011.
57. Hong, Y., Wu, C., & Wu, B. (2020). Effects of resistance exercise on symptoms, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy. *Integrative Cancer Therapies*, 19, 1534735420954912.

58. Huang, K., Cai, H. L., Bao, J. P., & Wu, L. D. (2020). Dehydroepiandrosterone and age-related musculoskeletal diseases: Connections and therapeutic implications. *Ageing Research Reviews*, 62, 101132.
59. Humphrey, J. D., & Schwartz, M. A. (2021). Vascular mechanobiology: homeostasis, adaptation, and disease. *Annual review of biomedical engineering*, 23(1), 1-27.
60. Inglis, J. E., Lin, P. J., Kerns, S. L., Kleckner, I. R., Kleckner, A. S., Castillo, D. A., ... & Peppone, L. J. (2019). Nutritional interventions for treating cancer-related fatigue: a qualitative review. *Nutrition and cancer*, 71(1), 21-40.
61. Irani, S. (2020). New insights into oral cancer—Risk factors and prevention: A review of literature. *International Journal of Preventive Medicine*, 11.
62. James, M. T., Levey, A. S., Tonelli, M., Tan, Z., Barry, R., Pannu, N., ... & Hemmelgarn, B. R. (2019). Incidence and prognosis of acute kidney diseases and disorders using an integrated approach to laboratory measurements in a universal health care system. *JAMA Network Open*, 2(4), e191795-e191795.
63. Jansen, F. M., Vavricka, S. R., den Broeder, A. A., de Jong, E. M., Hoentjen, F., & van Dop, W. A. (2020). Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. *United European gastroenterology journal*, 8(9), 1031-1044.
64. Jentzer, J. C., Bihorac, A., Brusca, S. B., Del Rio-Pertuz, G., Kashani, K., Kazory, A., ... & Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council. (2020). Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives. *Journal of the American College of Cardiology*, 76(9), 1084-1101.
65. Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. *The lancet*, 398(10302), 786-802.
66. Kalantar-Zadeh, K., Lockwood, M. B., Rhee, C. M., Tantisattamo, E., Andreoli, S., Balducci, A., ... & Li, P. K. T. (2022). Patient-centred approaches for the management of unpleasant symptoms in kidney disease. *Nature Reviews Nephrology*, 18(3), 185-198.
67. Katabathina, V. S., Menias, C. O., Khanna, L., Murphy, L., Dasyam, A. K., Lubner, M. G., & Prasad, S. R. (2019). Hereditary gastrointestinal cancer syndromes: role of imaging in screening, diagnosis, and management. *Radiographics*, 39(5), 1280-1301.
68. Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., ... & Schaefferbeke, T. (2018). Rheumatic disorders associated with immune checkpoint

- inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. *Annals of the rheumatic diseases*, 77(3), 393-398.
69. Krueger, K. M., Ison, M. G., & Ghossein, C. (2020). Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. *American Journal of Kidney Diseases*, 75(3), 417-425.
70. Lahousse, A., Roose, E., Leysen, L., Yilmaz, S. T., Mostaqim, K., Reis, F., ... & Nijs, J. (2021). Lifestyle and pain following cancer: state-of-the-art and future directions. *Journal of clinical medicine*, 11(1), 195.
71. Lam, G. A., Albarrak, H., McColl, C. J., Pizarro, A., Sanaka, H., Gomez-Nguyen, A., ... & Paes Batista da Silva, A. (2023). The oral-gut axis: periodontal diseases and gastrointestinal disorders. *Inflammatory bowel diseases*, 29(7), 1153-1164.
72. Lameire, N. H., Levin, A., Kellum, J. A., Cheung, M., Jadoul, M., Winkelmayer, W. C., ... & Srisawat, N. (2021). Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney international*, 100(3), 516-526.
73. Larsson, S. C., & Burgess, S. (2021). Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies. *BMC medicine*, 19, 1-10.
74. Larsson, S. C., & Burgess, S. (2022). Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies. *EBioMedicine*, 82.
75. Lee, P., Chandel, N. S., & Simon, M. C. (2020). Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nature reviews Molecular cell biology*, 21(5), 268-283.
76. Lewis, R., Gómez Álvarez, C. B., Rayman, M., Lanham-New, S., Woolf, A., & Mobasheri, A. (2019). Strategies for optimising musculoskeletal health in the 21 st century. *BMC musculoskeletal disorders*, 20, 1-15.
77. Liem, R. I., Lanzkron, S., D. Coates, T., DeCastro, L., Desai, A. A., Ataga, K. I., ... & Mustafa, R. A. (2019). American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood advances*, 3(23), 3867-3897.
78. Luan, X., Tian, X., Zhang, H., Huang, R., Li, N., Chen, P., & Wang, R. (2019). Exercise as a prescription for patients with various diseases. *Journal of sport and health science*, 8(5), 422-441.

79. Luttrell, T. (2024). Trauma and Inflammation of Soft Tissue: Rehabilitation and Wound Healing and Remodeling of Collagen. In *Foundations of Orthopedic Physical Therapy* (pp. 2-37). Routledge.
80. Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020, September). Pulmonary hypertension: a brief guide for clinicians. In *Mayo Clinic Proceedings* (Vol. 95, No. 9, pp. 1978-1988). Elsevier.
81. Mannes, M., Schmidt, C. Q., Nilsson, B., Ekdahl, K. N., & Huber-Lang, M. (2021, December). Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis. In *Seminars in immunopathology* (pp. 1-16). Springer Berlin Heidelberg.
82. Marotto, D., Atzeni, F., Ardizzone, S., Monteleone, G., Giorgi, V., & Sarzi-Puttini, P. (2020). Extra-intestinal manifestations of inflammatory bowel diseases. *Pharmacological Research*, 161, 105206.
83. Mata, R., Yao, Y., Cao, W., Ding, J., Zhou, T., Zhai, Z., & Gao, C. (2021). The dynamic inflammatory tissue microenvironment: Signaling and disease therapy by biomaterials. *Research*.
84. Meduri, G. U., & Chrousos, G. P. (2020). General adaptation in critical illness: glucocorticoid receptor-alpha master regulator of homeostatic corrections. *Frontiers in endocrinology*, 11, 161.
85. Meizlish, M. L., Franklin, R. A., Zhou, X., & Medzhitov, R. (2021). Tissue homeostasis and inflammation. *Annual review of immunology*, 39(1), 557-581.
86. Modi, Z. J., Lu, Y., Ji, N., Kapke, A., Selewski, D. T., Dietrich, X., ... & Gipson, D. S. (2019). Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system. *JAMA cardiology*, 4(4), 353-362.
87. Mullens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C., Lassus, J., ... & Coats, A. (2020). Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. *European journal of heart failure*, 22(4), 584-603.
88. Murphey, M. D., & Kransdorf, M. J. (2021). Staging and classification of primary musculoskeletal bone and soft-tissue tumors according to the 2020 WHO update, from the AJR special series on cancer staging. *American Journal of Roentgenology*, 217(5), 1038-1052.
89. Nadim, M. K., Forni, L. G., Bihorac, A., Hobson, C., Koyner, J. L., Shaw, A., ... & Kellum, J. A. (2018). Cardiac and vascular surgery—associated acute kidney injury: the 20th

- international consensus conference of the ADQI (acute disease quality initiative) group. *Journal of the American Heart Association*, 7(11), e008834.
90. Naik, S., & Fuchs, E. (2022). Inflammatory memory and tissue adaptation in sickness and in health. *Nature*, 607(7918), 249-255.
91. Nanchal, R., Subramanian, R., Karvellas, C. J., Hollenberg, S. M., Peppard, W. J., Singbartl, K., ... & Alhazzani, W. (2020). Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. *Critical care medicine*, 48(3), e173-e191.
92. Natoli, G., & Ostuni, R. (2019). Adaptation and memory in immune responses. *Nature immunology*, 20(7), 783-792.
93. Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., ... & American Heart Association. (2023). Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. *Circulation*, 148(20), 1606-1635.
94. Neag, M. A., Mocan, A., Echeverría, J., Pop, R. M., Bocsan, C. I., Crişan, G., & Buzoianu, A. D. (2018). Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. *Frontiers in pharmacology*, 9, 557.
95. Neagu, M., Constantin, C., Popescu, I. D., Zipeto, D., Tzanakakis, G., Nikitovic, D., ... & Tsatsakis, A. M. (2019). Inflammation and metabolism in cancer cell—mitochondria key player. *Frontiers in Oncology*, 9, 348.
96. Niec, R. E., Rudensky, A. Y., & Fuchs, E. (2021). Inflammatory adaptation in barrier tissues. *Cell*, 184(13), 3361-3375.
97. Ogbechi, J., Clanchy, F. I., Huang, Y. S., Topping, L. M., Stone, T. W., & Williams, R. O. (2020). IDO activation, inflammation and musculoskeletal disease. *Experimental Gerontology*, 131, 110820.
98. Oldroyd, A. G., Allard, A. B., Callen, J. P., Chinoy, H., Chung, L., Fiorentino, D., ... & Aggarwal, R. (2021). A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. *Rheumatology*, 60(6), 2615-2628.
99. Oliveira, C. B., Maher, C. G., Franco, M. R., Kamper, S. J., Williams, C. M., Silva, F. G., & Pinto, R. Z. (2020). Co-occurrence of chronic musculoskeletal pain and cardiovascular diseases: a systematic review with meta-analysis. *Pain Medicine*, 21(6), 1106-1121.
100. Ostermann, M., Bellomo, R., Burdmann, E. A., Doi, K., Endre, Z. H., Goldstein, S. L., ... & Zarbock, A. (2020). Controversies in acute kidney injury: conclusions from a Kidney

- Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney international*, 98(2), 294-309.
101. Palmer, W., Bancroft, L., Bonar, F., Choi, J. A., Cotten, A., Griffith, J. F., ... & Pfirrmann, C. W. (2020). Glossary of terms for musculoskeletal radiology. *Skeletal radiology*, 49, 1-33.
102. Paolino, S., Pacini, G., Patanè, M., Alessandri, E., Cattelan, F., Goegan, F., ... & Cutolo, M. (2019). Interactions between microbiota, diet/nutrients and immune/inflammatory response in rheumatic diseases: focus on rheumatoid arthritis. *Reumatologia/Rheumatology*, 57(3), 151-157.
103. Pawa, S., Banerjee, P., Kothari, S., D'Souza, S. L., Martindale, S. L., Gaidos, J. K., ... & Burke, C. A. (2021). Are all endoscopy-related musculoskeletal injuries created equal? Results of a national gender-based survey. *Official journal of the American College of Gastroenterology| ACG*, 116(3), 530-538.
104. Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., ... & Wray, W. (2021). 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Canadian journal of cardiology*, 37(8), 1129-1150.
105. Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022). Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease—novel insights into cellular communication circuits. *Journal of hepatology*, 77(4), 1136-1160.
106. Platz, E., Jhund, P. S., Girerd, N., Pivetta, E., McMurray, J. J., Peacock, W. F., ... & Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. (2019). Expert consensus document: reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. *European journal of heart failure*, 21(7), 844-851.
107. Qu, F., Guilak, F., & Mauck, R. L. (2019). Cell migration: implications for repair and regeneration in joint disease. *Nature Reviews Rheumatology*, 15(3), 167-179.
108. Rajendran, P., Chen, Y. F., Chen, Y. F., Chung, L. C., Tamilselvi, S., Shen, C. Y., ... & Huang, C. Y. (2018). The multifaceted link between inflammation and human diseases. *Journal of cellular physiology*, 233(9), 6458-6471.
109. Ranasinghe, R., Mathai, M., & Zulli, A. (2022). A synopsis of modern-day colorectal cancer: Where we stand. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1877(2), 188699.

110. Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S., Lentine, K. L., ... & American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. (2019). Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*, 139(16), e840-e878.
111. Renzi, C., Kaushal, A., Emery, J., Hamilton, W., Neal, R. D., Rachet, B., ... & Lyratzopoulos, G. (2019). Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. *Nature reviews clinical oncology*, 16(12), 746-761.
112. Reyes-Hinojosa, D., Lozada-Pérez, C. A., Cuevas, Y. Z., López-Reyes, A., Martínez-Nava, G., Fernández-Torres, J., ... & Martínez-Flores, K. (2019). Toxicity of cadmium in musculoskeletal diseases. *Environmental Toxicology and Pharmacology*, 72, 103219.
113. Ribaldone, D. G., Pellicano, R., & Actis, G. C. (2019). The gut and the Inflammatory Bowel Diseases inside-out: The extra-intestinal manifestations. *Minerva gastroenterologica e dietologica*, 309-318.
114. Rivera-Izquierdo, M., Cabeza, L., Láinez-Ramos-Bossini, A., Quesada, R., Perazzoli, G., Alvarez, P., ... & Melguizo, C. (2019). An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders. *Expert Opinion on Biological Therapy*, 19(3), 233-248.
115. Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., ... & Carmelina Investigators. (2019). Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. *Jama*, 321(1), 69-79.
116. Rossi, F., Tortora, C., Paoletta, M., Marrapodi, M. M., Argenziano, M., Di Paola, A., ... & Iolascon, G. (2022). Osteoporosis in childhood cancer survivors: physiopathology, prevention, therapy and future perspectives. *Cancers*, 14(18), 4349.
117. Ryan, A. M., & Sullivan, E. S. (2021). Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. *Proceedings of the Nutrition Society*, 80(1), 73-91.
118. Sange, A. H., Srinivas, N., Sarnaik, M. K., Modi, S., Pisipati, Y., Vaidya, S., ... & Sange, I. (2021). Extra-intestinal manifestations of inflammatory bowel disease. *Cureus*, 13(8).
119. Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020). Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. *Journal of clinical medicine*, 9(5), 1417.

120. Sarnak, M. J., Amann, K., Bangalore, S., Cavalcante, J. L., Charytan, D. M., Craig, J. C., ... & Conference Participants. (2019). Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. *Journal of the American College of Cardiology*, 74(14), 1823-1838.
121. Savira, F., Magaye, R., Liew, D., Reid, C., Kelly, D. J., Kompa, A. R., ... & Wang, B. H. (2020). Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. *British journal of pharmacology*, 177(13), 2906-2922.
122. Schieda, N., Blauchman, J. I., Costa, A. F., Glikstein, R., Hurrell, C., James, M., ... & Hiremath, S. (2018). Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. *Canadian journal of kidney health and disease*, 5, 2054358118778573.
123. Serhan, C. N., Gupta, S. K., Perretti, M., Godson, C., Brennan, E., Li, Y., ... & Wolkenhauer, O. (2020). The atlas of inflammation resolution (AIR). *Molecular aspects of medicine*, 74, 100894.
124. Sharma, A., Zhao, X., Hammill, B. G., Hernandez, A. F., Fonarow, G. C., Felker, G. M., ... & DeVore, A. D. (2018). Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines–heart failure registry. *Circulation: Heart Failure*, 11(6), e004646.
125. Silveira, E. A., da Silva Filho, R. R., Spexoto, M. C. B., Haghighatdoost, F., Sarrafzadegan, N., & de Oliveira, C. (2021). The role of sarcopenic obesity in cancer and cardiovascular disease: a synthesis of the evidence on pathophysiological aspects and clinical implications. *International journal of molecular sciences*, 22(9), 4339.
126. Song, Y., Wu, Z., & Zhao, P. (2022). The function of metformin in aging-related musculoskeletal disorders. *Frontiers in Pharmacology*, 13, 865524.
127. Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., ... & Van Hare, G. F. (2019). 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 73(12), 1494-1563.
128. Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., ... & Van Hare, G. F. (2019). 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 73(12), e81-e192.

129. Sturgeon, K. M., Mathis, K. M., Rogers, C. J., Schmitz, K. H., & Waning, D. L. (2019). Cancer-and chemotherapy-induced musculoskeletal degradation. *JBMR plus*, 3(3), e10187.
130. Suzuki, K. (2019). Chronic inflammation as an immunological abnormality and effectiveness of exercise. *Biomolecules*, 9(6), 223.
131. Tsutsui, H., Isobe, M., Ito, H., Okumura, K., Ono, M., Kitakaze, M., ... & Yamashina, A. (2019). JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version—. *Circulation Journal*, 83(10), 2084-2184.
132. Tucker-Bartley, A., Lemme, J., Gomez-Morad, A., Shah, N., Veliu, M., Birklein, F., ... & Upadhyay, J. (2021). Pain phenotypes in rare musculoskeletal and neuromuscular diseases. *Neuroscience & Biobehavioral Reviews*, 124, 267-290.
133. Turakhia, M. P., Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., ... & Wanner, C. (2018). Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *European heart journal*, 39(24), 2314-2325.
134. Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022). The global burden of cardiovascular diseases and risk: a compass for future health. *Journal of the American College of Cardiology*, 80(25), 2361-2371.
135. VanWagner, L. B., Harinstein, M. E., Runo, J. R., Darling, C., Serper, M., Hall, S., ... & Hammel, L. L. (2018). Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. *American Journal of Transplantation*, 18(1), 30-42.
136. Varela, M. L., Mogildea, M., Moreno, I., & Lopes, A. (2018). Acute inflammation and metabolism. *Inflammation*, 41, 1115-1127.
137. Vasconcelos, D. P., Águas, A. P., Barbosa, M. A., Pelegrín, P., & Barbosa, J. N. (2019). The inflammasome in host response to biomaterials: Bridging inflammation and tissue regeneration. *Acta biomaterialia*, 83, 1-12.
138. Villeneuve, D. L., Landesmann, B., Allavena, P., Ashley, N., Bal-Price, A., Corsini, E., ... & Tschudi-Monnet, F. (2018). Representing the process of inflammation as key events in adverse outcome pathways. *Toxicological sciences*, 163(2), 346-352.
139. Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019). Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. *Molecular aspects of medicine*, 65, 2-15.
140. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright, J. T. (2018). 2017

- CC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: areport of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 71(19), e127-e248.
141. Wiles, K., Chappell, L., Clark, K., Elman, L., Hall, M., Lightstone, L., ... & Bramham, K. (2019). Clinical practice guideline on
142. Wong, S. K., Chin, K. Y., & Ima-Nirwana, S. (2020). Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. *Phytomedicine*, 73, 152892.
143. Yang, Y. J., & Kim, D. J. (2021). An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia. *International journal of molecular sciences*, 22(5), 2604.
144. Zanelli, M., Pizzi, M., Sanguedolce, F., Zizzo, M., Palicelli, A., Soriano, A., ... & Ascani, S. (2021). Gastrointestinal manifestations in systemic mastocytosis: the need of a multidisciplinary approach. *Cancers*, 13(13), 3316.
145. Zhang, Q., & Cao, X. (2021). Epigenetic remodeling in innate immunity and inflammation. *Annual review of immunology*, 39(1), 279-311.
146. Zhang, S., Miller, D. D., & Li, W. (2021). Non-musculoskeletal benefits of vitamin D beyond the musculoskeletal system. *International journal of molecular sciences*, 22(4), 2128.
147. Zhang, S., Xing, M., & Li, B. (2019). Recent advances in musculoskeletal local drug delivery. *Acta biomaterialia*, 93, 135-151.
148. Zhao, H. M., Xie, Y. X., Wang, C., Chinese Association of Rehabilitation Medicine, Respiratory Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, & Cardiopulmonary Rehabilitation Group of Chinese Society of Physical Medicine and Rehabilitation. (2020). Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019. *Chinese medical journal*, 133(13), 1595-1602.
149. Ziade, N., El Khoury, B., Zoghbi, M., Merheb, G., Abi Karam, G., Mroue', K., & Messaykeh, J. (2020). Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study. *Scientific reports*, 10(1), 7683.
150. Zügel, M., Maganaris, C. N., Wilke, J., Jurkat-Rott, K., Klingler, W., Wearing, S. C., ... & Hodges, P. W. (2018). Fascial tissue research in sports medicine: from molecules to tissue adaptation, injury and diagnostics: consensus statement. *British journal of sports medicine*, 52(23), 1497-1497.